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Abstract 
The successful development of nanomaterials illustrates the considerable interest in the 
development of new molecular probes for medical diagnosis and imaging. Substantial 
progress was made in synthesis protocol and characterization of these materials whereas 
toxicological issues are sometimes incomplete. Nanoparticle-based contrast agents tend to 
become efficient tools for enhancing medical diagnostics and surgery for a wide range of 
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imaging modalities. Multimodal nanoparticles (NPs) are much more efficient than 
conventional molecular-scale contrast agents. They provide new abilities for in vivo detection 
and enhanced targeting efficiencies through longer circulation times, designed clearance 
pathways, and multiple binding capacities. Properly protected, they can safely be used for the 
fabrication of various functional systems with targeting properties, reduced toxicity and 
proper removal from the body. This review mainly describes the advances in the development 
of mono- to multimodal NPs and their in vitro and in vivo relevant biomedical applications 
ranging from imaging and tracking to cancer treatment. Besides specific applications for 
classical imaging, (MRI, PET, CT, US, PAI) are also mentioned less common imaging 
techniques such as terahertz molecular imaging (THMI) or ion beam analysis (IBA). 
Perspectives on multimodal theranostic NPs and their potential for clinical advances are also 
mentioned.  
 
 
Keywords. Nanoparticles, Multimodal Bio-imaging, Characterization, Multifunctionality, 
Theranostic.  
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Introduction 
Nanoparticles as contrast agents tend to become standard practice in the field of imaging, for 
both bio-imaging and medical imaging [1]. They are used to improve the enhancement of 
image contrast as compared to molecular species and improve the visibility of features that 
would otherwise be difficult to detect. They go on receiving considerable attention in this 
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field for their potential as contrast agents, [2-9] offering many advantages compared to more 
conventional chemical agents such as greater biocompatibility and reduced toxicity [8, 10-13]. 
Noninvasive imaging and minimally invasive in vivo bio-imaging techniques are of course the 
most valuable tools for clinical diagnostics. Clinical Imaging modalities generally include 
complementary techniques [14] such as: optical imaging, [15-23] magnetic resonance imaging 
(MRI), [24-27] computed tomography (CT), [28] ultrasound imaging (USI) [29-33] positron 
emission tomography (PET) [34-37] and single photon emission computed tomography 
(SPECT) [38-40]. Other techniques are also scrutinized, for example multi-photon plasmon 
resonance microscopy, [41] optical coherence tomography (OCT), [42] surface enhanced 
Raman spectroscopy (SERS), [15, 43-47] and diffuse optical spectroscopy [48]. Some of 
these techniques enable entire-organism anatomical imaging (e.g. MRI or PET) and others 
provide more specific molecular imaging (e.g., optical fluorescence or USI) at subcellular 
resolution. Combination of these different tools should allow a better early-stage cancer 
diagnosis, guided stem cell therapies, drug delivery, pathogen detection, gene therapy, image-
guided surgery, and cancer staging, [49] in addition to many other clinically relevant 
procedures, diagnostics, and therapies. 
To help improving these techniques resolution, nanoparticles (NPs) emerge as very powerful 
probes for both in vivo imaging in medical and biological diagnostics. Several NP-based 
contrast agents (CAs) have helped generating breakthroughs as compared to common CAs 
improving their properties and detection limits, in a broad array of imaging modalities. The 
specifications of an ideal NP CA are numerous. It should exhibit colloidal stability in 
biological in vivo media, non-dependence on solvent polarity, ionic strength, pH, or 
temperature. Other properties such as limited nonspecific binding, resistance to reticulo-
endothelial system (RES) uptake, and easy clearance mechanisms are also required. High 
sensitivity and selectivity for the target (e.g., antigen, cell, tissue) with good contrast quality 
(high signal-to-noise ratio, (SNR)) and sufficiently long blood circulation times are also 
mandatory. In other words, this NP should have the adapted long-term quantitative imaging at 
low doses and be safely cleared from the body after imaging completion.  
 
In Table 1 besides the characteristics of the most commonly used in vivo imaging modalities 
in the clinical field are also gathered some more recent ones such as TeraHetz molecular 
imaging (THMI), Particle induced x-ray emission (PIXE), Rutherford Backscattering 
Spectrometry (RBS), and Scanning Transmission Ion Microscopy (STIM). Each type of in 
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vivo imaging technique has its own advantages and limitations, which include spatial and/or 
temporal resolution, sensitivity, SNR, penetration depth in tissue, and quantitative accuracy.  
 
Table 1. List of commonly used bio-imaging techniques (partly adapted from Refs [50] and 
[51]). 
Technique Typical NP label Signal 
measured 
Resolution Depth Sensitivity 
(moles of 
 label 
detected) 
Advantages Cost Main limitation 
Optical 
and NIRF 
QDs, dye-doped 
NPs, upconverting 
NPs, SWNTs and 
other carbon-based 
nanomaterials 
(dots, diamonds, 
graphene) 
Light, 
particularly 
in the near-
infrared 
1–3 mm <1 cm 10−12  High 
sensitivity 
Multicolor 
imaging 
Low Poor depth 
penetration 
Poor spatial 
resolution 
MRI Iron oxide NPs, 
Gd(III)-doped NPs, 
NP-based CEST and 
hyperpolarized 
probes (e.g., 129Xe)  
Alterations 
in magnetic 
fields 
25–100 
μm 
No 
limit 
10−9–10−6  High spatial 
resolution 
Hig
h 
Low sensitivity, 
cannot follow 
many labels, time 
consuming 
PET NPs incorporating 
radioisotopes (e.g., 
18F, 11C, 64Cu, 124I)  
Positron 
from 
radionuclide
s 
1–2 mm No 
limit 
10−15  High 
sensitivity 
quantitative 
entire body 
scanning 
Hig
h 
Can detect only 
one radionuclide, 
requires 
radioactivity 
SPECT NPs incorporating 
radioisotopes (e.g., 
99mTc, 111In)  
γ-rays 1–2 mm No 
limit 
10−14  High 
sensitivity 
 
Hig
h 
Uses radioactivity 
Poor spatial 
resolution 
CT Iodinated NPs, gold 
NPs, iron oxide-
doped 
nanomaterials 
X-rays 50 μm No 
limit 
10−6  High spatial 
resolution 
Hig
h 
Poor resolution of 
soft tissues 
Not quantitative 
US Microbubbles, 
nanoemulsions, 
silica NPs, 
polystyrene NPs 
Sound 50 μm Several 
cm 
10−8  Real-time 
measurement 
Low Poor image 
contrast, works 
poorly in air-
containing organs 
PATa Gold nanoshells, 
gold nanocages, 
gold nanorods, gold  
NPs, SWNTs, dye-
doped NPs 
Sound 50 μm <5 cm 10−12  multiscale 
imaging 
anatomical, 
functional, 
molecular 
and fluid-
dynamic 
imaging 
Low Information 
processing and 
machines still 
being optimized 
THMIb Gold nanorods 
Metal oxide NPs 
Heat 
variation 
100 µm No 
limit 
10−6  High 
sensitivity 
molecular 
network 
information 
based on 
hydrogen 
bonding 
  
Ion beam 
Analysis 
[52] 
(PIXE,c 
RBS,d 
STIMe 
[53]) 
 Metal 
Metal oxide NPs 
 
 
H+  beam 
He+ ions 
 
 
 
>1 µm 
50-200nm 
250 nm 
  
 
20 µm 
 
 
 
Traces of 
elements 
0.1 to 10 ppm 
High 
sensitivity 
Elemental 
mapping 
Quantitative  
high Restricted to in 
vitro studies 
a) PAT: photoacoustic tomography 
b) THMI: TeraHetz molecular imaging 
c) PIXE: Particle induced x-ray emission  
d) RBS: Rutherford Backscattering Spectrometry 
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e) STIM: Scanning Transmission Ion Microscopy 
 
A close look at the literature reveals that basically there are some types of NPs which always 
appear as contrast agents: metal NPs (mostly gold) and metal oxide NPs. They appear either 
as active agents such as iron oxide in MRI for example, or as carriers of the active agent like 
silica NPs.  
In this review, our aim is to give a state of the art of the most recent works on the subject 
including the most recent techniques, and to categorize these NPs according to their field of 
activities: MRI, near-infrared fluorescence (NIRF) imaging, positron emission tomography 
(PET), computed tomography (CT), ultrasound (US), photoacoustic imaging (PAI) and 
TeraHetz molecular imaging (THMI). Table 1 highlights the current NP-based contrast labels 
for each of these techniques.  The accent will be stressed on multifunctional/multimodal NPs 
and theranostic NPs; their potential for clinical use, will also be discussed. The reader can also 
get information on numerous imaging techniques in various reviews [14, 16, 28, 54-56].  
1 Magnetic resonance imaging (MRI) 
MRI is typically the noninvasive and nonionizing imaging method that provides both 
physiological and pathological information about living tissue, usually by measuring water 
proton relaxation rates. MRI offers high soft tissue contrast especially with contrast agents 
(CAs) and provides deep tissue imaging with high spatial resolution (~ 50 μm). The major 
drawback of this technique is its low sensitivity requiring the use of these CAs whose role is 
to alter relaxation processes. CAs are divided in two classes: those that increase the T1 signal 
in T1-weighted images (so-called positive contrast agents, giving a bright contrast), and those 
that reduce the T2 signal in T2-weighted images (so-called negative contrast agents, leading to 
a dark contrast). The effectiveness of a particular probe is defined by its longitudinal (r1) and 
transverse (r2) relaxivities. T2 agents are not so convenient for diagnosis because they provide 
dark contrast which is not so easy to interpret for clinicians. In contrast, the signal produced 
by T1 (paramagnetic) contrast agents, can easily be detected with high spatial resolution.  
1.1 T1 NPs-based contrast agents 
Three important requirements for the design of highly sensitive paramagnetic NPs have been 
identified: (i) a large number of labile water molecules coordinated to the metal; (ii) optimum 
residence lifetime at the metal site; and (iii) a slow tumbling motion of the NP containing the 
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contrast agent.[57] To fulfill these requirements, a well-known T1 CA, Gd(III), has been 
incorporated into various nanomaterials, for example silica and perfluorocarbon nanoparticles, 
carbon nanotubes, [58] carbon nanodots, [59] and nanodiamonds, [60] which all exhibit high 
MR contrast because of a high payload of gadolinium ions and a slow tumbling motion of 
particles. For a Gd(III) complex attached to nanodiamonds, a 10-fold relaxivity increase was 
observed compared with the monomeric Gd(III) complex. Gadolinium chelates were grafted 
on to gold for dual imaging [61] and mesoporous silica NPs, [62, 63] leading to a high local 
concentration of CA as compared to molecular complexes. They were associated with other 
lanthanides to provide particles capable of dual imaging, [64, 65] with drug for therapeutic 
function [66] or with gene in microglial cells for therapy [67]. 
However, gadolinium loading on these systems strongly depends on the number of anchoring 
sites available on the surface of the NPs even if Gd (III) could also recently be dispersed in a 
carbon matrix [59]. A way to solve this problem relies in the synthesis of Gd–based 
paramagnetic NPs, [68] such as Ln2O3, GdF3, and GdPO4 [26, 69, 70] which yield high 
magnetic moments because of the abundance of paramagnetic ions on their surfaces.  
Transition metal oxide (MnO) NPs have recently been developed by various groups for T1-
contrast imaging of brain tumors, [71] in addition to the liver and kidney [58, 72]. Hollow 
MnO NPs could also carry drug molecules in their cavities for simultaneous imaging and 
therapy applications [73]. 
Silica has been recognized as a good candidate for a coating material because it is relatively 
biocompatible and resistant to biodegradation [74, 75]. Among others, mesoporous silica-
coated hollow MnO NPs (HMnO@mSiO2) have been synthesized and characterized. These 
nanoparticles show a significantly higher r1 relaxivity than other existing manganese oxide 
nanoparticle based contrast agents. The porous SiO2 coating enables water exchange across the 
shell and the high surface-to-volume ratio of the hollow structure increases the water 
accessibility to the manganese core and consequently enhances T1contrast. HMnO@mSiO2 
nanoparticles also showed potential MRI cell tracking using positive contrast [75]. 
With relaxivities that depend on the biological environment, “smart” T1 MR probes that 
respond to their surroundings have been pursued extensively [57]. This class of probe 
primarily consists of Gd(III)-based complexes; incorporation of these smart probes into NPs 
will further enhance their efficiency in molecular imaging applications. Very recently, the use 
of an improved hydrolysis method of inorganic salts assisted by incubation in a water bath, 
led to water-soluble extremely small-sized metal-iron oxide nanoparticles iron oxide based 
NPs: MFe2O4 (ESIONs) (M = Fe, Zn, Ni) NPs with average sizes of 4 to 5 nm [76, 77]. The r1 
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relaxivities and the r2/r1 ratios of these nanoparticles were more than 5 and less than 3, 
respectively, which indicated that they were good candidates as T1-weighted MRI contrast 
agents. As an example, the γ-Fe2O3 ESIONs were synthesized by controlled thermal 
decomposition of iron-oleate complex in the presence of oleyl alcohol via heat-up process. 
These ESIONs revealed a maghemite crystal structure with a magnetization much smaller 
than that of 12 nm-sized iron oxide NPs due to their small magnetic moment and a spin 
canting effect. ESIONs have a large number of surface Fe3+ ions with 5 unpaired electrons 
exhibited high r1 relaxivities of > 4.7 mM-1 s-1 and low r2/r1 ratios of < 6.2. Their high r1 
relaxivity and long blood circulation time enabled high-resolution blood pool T1-weighted 
MR imaging of various blood vessels with sizes down to 0.2 mm. With their low toxicity, 
high r1 relaxivity, long blood half-life, they could become the new T1 MRI contrast agents for 
various clinical applications including diagnosis of the myocardial infarction, renal failure, 
atherosclerotic plaque, thrombosis, and angiogenesis of tumor cells. 
 
1.2 T2 NPs-based contrast agents 
Beside these lanthanide derivatives, magnetic NP-based probes have been developed for MRI 
to achieve high tissue contrast and to improve imaging sensitivity. The most popular material 
studied for T2 (superparamagnetic) contrast agents is based on iron oxide NPs (maghemite and 
magnetite), which are generally coated with dextran, PEG, or other polymers, and are used for 
clinical MRI [78-82]. Based on their size, these NPs have been classified as magnetic iron 
oxide NPs (MION, μm), superparamagnetic iron oxide (SPIO, hundreds of nm), ultra-small 
paramagnetic iron oxide (USPIO, <50 nm) and down.  
SPIO contrast agents have been essentially used clinically for diagnosis of liver diseases, [83] 
whereas USPIO probes are generally used for lymph-node imaging, angiography, and blood-
pool imaging [84-89]. Besides their clinical use, MRI contrast agents based on iron oxide 
nanoparticles are actually developed for studying biological processes: Significant 
contributions in this research area have illustrated the potential use of these particles for 
molecular and cellular imaging applications [78, 80, 82, 90-94].  
As an example, [95] Transferrin(Tf)-SPIONs were injected intravenously in a rat bearing two 
tumors with different levels of Transferrin receptor (TfR) and MRI performed (Figure 1). The 
decrease in T2 relaxation time was much more pronounced for the tumor expressing high 
levels of the TfR compared to the tumor expressing low levels of the receptor showing that 
both in vitro and in vivo MRI can be significantly improved when iron oxide NPs are targeted 
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towards cell surface receptors that are overexpressed in tumors. A better understanding of 
imaging biology could significantly influence the design, synthesis, and efficacy of MRI 
probes. 
Figure 1 here 
 
The efficiency of iron oxide probes as T2 contrast agent is size-dependent and increases with 
higher particle crystallinity [26, 79, 86, 96, 97]. However, these NPs generally synthesized at 
low temperatures, have poor crystallinity associated with small size, and lack of 
monodispersity, as also found for other nanomaterials [98].  
Another challenge for this class of contrast agents is the development of efficient methods for 
their dispersion in biological media and surface functionalization for biological targeting. 
Their encapsulation in a silica coating [99] may be a good option since it provides colloidal 
stability in biological solutions by avoiding inter-particle interactions and agglomeration. 
Furthermore, it can act as an anchor for the binding of biological vectors at the NPs surface. 
The thickness of the silica shell has also a strong influence on the physical properties of the 
NPs, especially in terms of contrast agent efficacy for magnetic resonance imaging. An ideal 
shell thickness was determined to be around 35 nm [100]. 
The inherent negative contrast associated with iron oxide NPs has limited their use in low-
signal regions of the body or in organs with intrinsically high magnetic susceptibilities, for 
example the lungs. To solve this problem, specific methods based on either pulse sequences 
[101, 102] design [103] or size control [76] of nanoparticles have been developed by 
researchers to generate bright contrast from iron oxide NPs.  
 
Other T2-based NPs contrast agents with improved magnetic and physicochemical properties 
have been developed such as paramagnetic dysprosium nanomaterials (nanoparticles and 
nanorods) [104, 105]. Their negligible r1 relaxivity enhances T2 MR imaging because in that 
case protons are nearly exclusively induced for T2 MR imaging at a negligible r1. Bimetallic 
ferrite NPs such as CoFe2O4, MnFe2O4, and NiFe2O4 NPs have been investigated as potential 
T2 contrast agents, and some of them, especially MnFe2O4 NPs have been found to display a 
very high magnetization and large T2 relaxivity values [106]. However, long term toxicity 
issues of these new nanomaterials have yet to be assessed. The key point for these NPs to 
serve as T1 or T2 agents is their size. Indeed, some of these ferrites (Fe3O4, ZnFe2O4 and 
NiFe2O4 ) when displaying a 4-5 nm size have recently been used as T1-weighted contrast 
agents for magnetic resonance imaging (MRI), see ref. [77]. 
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1.3 Other probes  
1.3.1 PARACEST nanoparticles 
Nanoparticle CAs are also now used as paramagnetic chemical exchange saturation transfer 
(PARACEST) agents when they display bound water signals that can exchange protons with 
the bulk water. PARACEST magnetic resonance imaging (MRI) relies on these exchangeable 
protons that resonate at a chemical shift which is clearly distinguishable from the bulk water 
signal due the paramagnetism of the particle. Radiofrequency pre-pulses when applied at an 
appropriate frequency saturate the exchangeable protons, which transfer into the bulk water 
pool and lead to reduced equilibrium magnetization allowing the image contrast to be 
switched ‘on’ and ‘off’ by a simple change of the pulse sequence parameters. To enhance the 
inherent insensitivity of MRI to PARACEST agents and improve the limit of detection for 
these agents, nanoscale carriers have been developed such as liposomes, dendrimers, 
polymers, adenovirus particles, and perfluorocarbon nanoparticles [79, 107-109]. The unique 
MRI properties of such nanoparticle systems generate a large interest in potential medical 
applications. 
1.3.2 Metal nanoparticles 
Ferromagnetic cobalt particles coated with gold (Au) for biocompatibility with a unique shape 
that enables optical absorption over a broad range of frequencies were used for MRI and 
photoacoustic tomography (PAT) so as to detect picomolar concentrations of nanoparticles. 
This dual-modality probe revealed very useful for detection of trace amounts of nanoparticles 
in biological tissues, in which MRI provides volume detection, whereas PAT performs edge 
detection [110]. Water-soluble cobalt oxide nanocrystals (CoO NCs) were obtained via a 
phase-transfer method with amphiphilic surfactants, such as anionic (sodium dodecyl sulfate, 
SDS), neutral (Pluronic F127, PF127) and cationic (cetyltrimethyl ammonium bromide, 
CTAB) [111]. A field-dependence of the magnetization on the type of surfactants showed the 
crucial role of the later. The longitudinal relaxivities (r1) and transverse relaxivities (r2) of the 
functionalized CoO NCs gave a r2/r1 of about 26 for CoO NCs functionalized with PF127 
showing some potential as T2 contrast agents. Cobalt ferrite NPs were also probed and 
displayed r2values higher than those of commercial ferumoxytol (91 mM-1 s-1) [111]. 
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2 Near-infrared fluorescence (NIRF) imaging 
Fluorescence imaging is a powerful molecular imaging technique, in which specific probes 
(i.e., fluorophores) are excited by incident radiation, usually in the visible or NIR, and emit 
energy at a (usually) lower energy than that of the excitation one. Despite its extremely high-
sensitivity detection and location of individual cells, mRNA, DNA, proteins, peptides, 
receptors, low-expressing cellular markers, it lacks the ability to provide anatomical 
resolution which is limited to 2-3 mm. As long as noninvasive imaging is concerned, 
fluorescence in the visible region is usable only for thin tissue sections. Deeper penetration 
depths required for most clinical applications need fluorescence-based techniques working in 
the NIR region (650-950 nm). In this NIR window, the absorption of water, hemoglobin, and 
lipids are at their minimum while auto-fluorescence and tissue scattering are low, enabling 
maximum light penetration and therefore high SNRs and sensitive detection. The light 
penetration depth depends on the type of tissue imaged; indeed skin and muscles are more 
transparent than organs with lots of vasculature (e.g., liver and spleen) because of absorption 
by hemoglobin. However, new advances in optical microscopy imaging techniques [18] have 
increased light penetration depths. The fluorophores must be bright with large Stokes shifts 
and high fluorescence quantum yields in the NIR, photostable as well as resistant to 
degradation in biological systems. Reviews on NPs used in in vivo fluorescence imaging are 
available [112-114].  
2.1 Quantum dots 
Quantum dots (QDs) exhibit broad absorption spectra, large absorption cross-sections, narrow 
and tunable emission spectra, high fluorescence quantum yields, and high photostability. 
[115] For all these reasons they are extremely popular in fluorescence imaging application. 
Their optical properties enable bi- [116] and even multicolor imaging, with different colored 
QDs used in a single assay with only one excitation source [117]. This is illustrated in Figure 
2, which clearly shows one of the first demonstrations of an in vivo simultaneous imaging of 
five different lymphatic flows and their trafficking to distinct lymph nodes. The versatility 
and use of multiple QDs in a single assay to visualize several lymphatic drainages in a mouse 
give rise to a new powerful tool.  
Figure 2 here 
  
12 
 
NIR emitting QDs comprise II–VI, IV–VI, and III–V compounds, such as CdSe, CdTe, HgTe, 
PbS, PbSe, PbTe, InAs, InP, and GaAs, as well as alloys of these materials, and core@shell 
structures, which can allow the emission tuning further and alter fluorescence lifetimes. 
Interesting probes are based on self-illuminating QDs, using fluorescence resonance energy 
transfer (FRET) from bioluminescent proteins conjugated to the QD [118, 119]. However, 
potential toxicity due to heavy metal ions has to be taken into account and may be detrimental 
for their use in clinical bio-imaging [120] and limit their use to in vitro and diagnostic assays. 
However, they have been used successfully in a sentinel lymph node mapping using 
intraoperative NIRF imaging [121] and more recently in non-human primates. [122] The 
authors showed that rhesus macaques injected with phospholipid micelle encapsulated 
CdSe/CdS/ZnS quantum dots did not exhibit evidence of toxicity. Blood and biochemical 
markers remained within normal ranges following treatment, and histology of major organs 
after 90 days showed no abnormalities. They deduced that acute toxicity of these quantum 
dots in vivo can be minimal even if chemical analysis revealed that most of the initial dose of 
cadmium still remained in the liver, spleen and kidneys after 90 days significant of slow 
breakdown and clearance of quantum dots. 
2.2 Dye-doped nanoparticles 
NIR dye-doped silica NPs are becoming popular choices of contrast agent for several reasons: 
silica NPs are optically transparent, water dispersible, biologically inert, nontoxic in the 
amorphous form, with well-established conjugation strategies to modify the surface to 
proteins, peptides, and other ligands for cellular receptors using silane chemistry. The use of 
such as matrix, in which many NIR fluorophores can be encapsulated, reduces the potential 
toxicity of these fluorescent probes and shields the NIR emitter from the aqueous 
environment, where the dye usually suffers from low fluorescence quantum yield, 
degradation, and unsatisfactory photostability. NIR-emitting dyes such as polymethines 
(Cy5.5, Cy7), indocyanine green (ICG), Alexa Fluor 750, and IRDye78 have already been 
incorporated into silica NPs. Encapsulation of multiple dyes within a single silica NP 
generates much brighter and more stable probes than those loaded with a single one. Dye-
doped silica NPs are usually synthesized by a sol–gel Stöber process or in microemulsion by 
simply adding the dye (or a modified form of the dye) to the silica-forming solution.[123] In 
addition, the use of mesoporous silica NPs enables the loading of an additional functions into 
the resulting pores, for example imaging probes of sentinel lymph nodes (SLNs) known as the 
first defense against primary tumor metastasis, [124] sensing [125] or a therapeutic agent 
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capable of photothermal ablation or a controlled drug release [126]. The covalent chemical 
grafting of lanthanide complexes on metal oxide nanoparticles was also recently performed 
and introduction of two different lanthanides gave bimodal contrast agents [64, 65, 127]. 
2.3 Upconverting nanomaterials 
Fluorescence imaging for small animals has received an increasing attention due to its ability 
to obtain anatomical and physiological details of living systems [128]. Most of the 
conventional fluorescence probes for bio-imaging are based on single-photon excitation, 
emitting low energy fluorescence when excited by high energy light. These single-photon 
probes exhibit some limitations such as (i) DNA damages with cell death due to long-term 
exposure to high energy excitation; (ii) low signal-to-noise ratio (SNR) due to the significant 
auto-fluorescence of the biological tissues; (iii) low penetration depth in the biological tissues. 
As opposed to visible light excitation, near-infrared (NIR) light excitation for in vivo imaging 
provides several advantages, such as deep penetration, weak autofluorescence, minimal 
photobleaching and low phototoxicity. In particular, two-photon-excited fluorescence imaging 
based on the anti-Stokes luminescence process revealed a useful strategy for imaging of the 
living brain to reduce autofluorescence [129].  
Nanocrystals with both excitation and photoluminescence (PL) in the biological optical 
transparency window combined with high quantum efficiency, spectral sharpness, and 
photostability, makes them extremely promising as optical bio-imaging probes. Rare-earth 
upconversion nanophosphors (UCNPs) belong to this new generation of luminescent probes 
for small-animal imaging. When excited by continuous-wave near-infrared light, they exhibit 
a unique narrow photoluminescence with higher energy. This upconversion luminescence 
(UCL) makes UCNPs promising as bio-imaging probes with attractive features, such as 
suppression of the auto-fluorescence from biological samples and a large penetration depth. 
As a result, UCNPs have emerged as novel imaging agents for small animals. Rules suitable 
to develop new optical labels for in vivo near-infrared optical imaging procedures were 
reported [130]. Later on, in their critical review, [131] Li et al. have recently reviewed the 
recent developments in the preparation, surface modification and bioconjugation chemistry of 
these UCNPs, and their applications in bio-imaging  and multimodality imaging of small 
animals. 
Among others, upconverting NPs developed as agents for in vivo fluorescence imaging, are 
doped with rare-earth ions derivatives.[132] They absorb NIR light (usually around 980 nm) 
and emit upconverted light at a higher energy, usually in the green or far-red/NIR, with long 
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fluorescence lifetime (μs to ms) [133, 134]. For example, polyethyleneimine-coated NaYF4: 
Yb,Er and NaYF4:Yb,Tm NPs when exposed to a 980-nm NIR laser could be used as 
upconverting NPs and evidence the first demonstration of use of upconversion fluorophores 
for cellular and tissue imaging via the imaging of visible fluorescence through mouse thigh 
muscle down to 10 mm depth [135]. Er-doped or Yb/Er-doped ceramic phosphors were 
synthesized and partly modified with polyethylene glycol to give dispersion and controlled 
interaction with the biological objects. Near infrared fluorescence of nematodes, mouse tissue 
and M1 cells was observed by detecting 1.5 μm emission from Er-doped in the ceramic 
phosphor [136]. In the same way, a new generation of 18F-labeled co-doped with 
Gd3+/Yb3+/Er3+ lanthanide nanoparticles of NaYF4 proved to be multimodality nanoprobes for 
UCL but also for PET, and MR imaging [137]. The presence of Yb3+ and Er3+ co-doped in the 
NaYF4 nanoparticles gave rise to intense UCL emission in the visible relaxivity for MRI. 
Successful labeling of the lanthanide nanoparticles with 18F gave a particle suitable for PET 
imaging. In vivo PET/MR entire-body imaging of small animals and ex vivo UCL imaging 
experiments on the biodistribution of 18F-labeled lanthanide NPs in small animals indicated 
the effectiveness of such NPs as a multimodality nanoprobe as discussed later on. 
Functionalized Y2O3-based upconverting NPs also form a promising platform for in vivo 
optical-based diagnostic imaging with an excellent photostability in the NIR as well as a low 
toxicity [138]. The Yb and Er-doped version of the yttrium oxide nanoparticles (Y2O3:YbEr-
NPs) exhibit beside a visible UCL, a strong NIR emission under NIR excitation (NIR-NIR 
emission): the particles shows bright green (550 nm) and red (660 nm) upconversion (UC) as 
well as near infrared (NIR) fluorescence (1550 nm) under 980 nm excitation [139, 140]. 
These NPs with NIR fluorescence at energies lower than their excitation wavelength could 
provide more advantages for bio-imaging applications. 
When judiciously coated some YF3:Yb3+/Er3+ NPs lead to upconversion luminescence in the 
NIR (831 nm) rather than in the visible, which enables greater penetration of the light. [141] 
Other examples include core@shell NdF3@SiO2, (α-NaYbF4:Tm3+)@CaF2, NaGdF4: 
Nd3+@NaGdF4 NPs which also have excitation and emission in the NIR range, and efficient 
deep tissue imaging of small animals. [133, 142] All of these materials were modified as to 
become dispersible in aqueous solutions and conjugated to relevant biomolecules for targeting 
purposes.  
2.4 Carbon nanomaterials 
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Carbon-based nanomaterials are also potential NIR contrast agents for in vivo imaging. The 
near-infrared photoluminescence intrinsic to the semiconducting single-walled carbon 
nanotubes (SWNTs) is ideal for biological imaging through the low autofluorescence and 
deep tissue penetration in the near-infrared region beyond 1 µm [143]. Their NIR 
fluorescence also offers a powerful approach for sensor development and in vivo or real-time 
imaging of biological systems [144]. They present an emission in the second IR window 
(1000-1350 nm), which would enable even deeper light penetration. The toxicity of SWNTs is 
still a controversy; their surface chemistry, therapeutics applications and toxicology as well as 
their use in biomedical imaging were reviewed [145]. A recent strategy to functionalize CNTs 
with bioactive glycoproteins, glycolipids and glycodendrimers led to a series of biocompatible 
and water-soluble CNTs which exhibit highly selective interactions with proteins and living 
cells. Their biomedical applications in cell sensing, gene delivery, bio-imaging , biosensors 
and bone tissue engineering were analyzed in a review paper [146]. Bioanalytical applications 
and bio imaging of carbon dots (CDs) have been reviewed [147]. They exhibit the advantages 
of being excited by single-photon (ultraviolet or near-ultraviolet) as well as multi-photon (red 
or near-infrared) excitation, and their luminescence properties are essentially due to surface 
defects. CDs were found to have emission in the visible region when they are passivated by 
polymer chains [148], doped with inorganic salts or photosensitizer [59, 149-152]. These 
materials are being investigated for optical imaging agents using both one and two-photon 
excitation [153]. Despite the fact that small animal or thin tissue imaging has been largely 
illustrated, clinical applications have not been yet proven.  
Colloidal diamond NPs (i.e., nanodiamonds) are yet another nanomaterial being investigated 
as potential in vivo fluorescent probes for biological and medical imaging. They have been 
shown to be biocompatible, not cytotoxic, and to have a highly reactive surface that is easily 
functionalized with biological entities [154]. These nanodiamonds emit single photon 
luminescence when stimulated by laser light owing to a number of different point defects 
based on different types of vacancies. Comprehensive reviews on nanodiamonds [155] their 
use as biolabels [156] and in nanomedecine [157] have been published.  
Similar to these luminescent carbon dots (C-dots), graphene quantum dots or graphene 
quantum discs (GQDs) have generated enormous excitement because of their superiority in 
chemical inertness, biocompatibility and low toxicity. Besides, GQDs, consisting of a single 
atomic layer of nano-sized graphite, have the excellent performances of graphene, such as 
high surface area, large diameter and better surface grafting using π–π conjugation and 
surface groups [158, 159]. 
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2.5 Other probes and NIRF techniques 
Luminescent porous silicon NPs (LPSiNPs) emitting at ~ 800 nm are also attractive 
candidates, excitable by NIR or two-photon excitation (Figure 3) and as opposed to most 
optically active nanomaterials (carbon nanotubes, gold nanoparticles and quantum dots), they 
can self-destruct in a mouse model into kidney cleared components in a relatively short period 
of time with no evidence of toxicity [160].  
Figure 3 here 
3 Positron emission tomography (PET) 
PET is a nuclear medicine imaging technique that produces a three-dimensional (3D) image 
or picture of functional processes in the body. The system detects pairs of gamma rays 
emitted indirectly by which is introduced into the body on a biologically active molecule. It 
relies on the detection of a positron emitted by radioisotopes (tracer); 3D images of the tracer 
concentration within the body are then constructed by computer analysis. Approved and used 
on a daily basis as a clinical molecular imaging technique with a resolution of 1-2 mm, [54] it 
presents however a relatively low spatial resolution which needs be improved. However, PET 
exhibits the highest sensitivity of all imaging modalities which enables quantification of the 
local concentration of radionuclide tracer, with only a few trace isotopes [55, 161]. 
Furthermore, PET penetration depth is unlimited, so the probe can always be imaged, 
irrespective of the target location. Especially important in cancer imaging and research, PET 
is capable of detecting molecular changes that are occurring in the body before the 
macroscopic disease is observed [37, 89, 162] and of monitoring disease progression after 
treatment (i.e., tumor response to therapy) [163].  
Over the past decades, positron emitter labeled nanoparticles have been widely used and 
substantially improved in a wide range of diagnostic biomedical research. One of the main 
challenges in this field is now to develop disease-specific nanoprobes with facile and robust 
radiolabeling strategies. These nanoprobes should also provide (i) imaging stability, (ii) 
enhanced sensitivity for disease early stage detection, (iii) optimized in vivo pharmacokinetics 
for reduced nonspecific organ uptake, and (iv) improved targeting for high efficacy. A variety 
of nanoparticles have been engineered and explored for diagnostic and therapeutic potential in 
various diseases and lately reviewed [164]. They are essentially labeled with PET isotopes for 
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cardiovascular, pulmonary, and tumor imaging, as well as for pharmacokinetic evaluation 
[161].  
3.1 Radionuclide Labeled Nanoparticles 
Common isotopes that can be chelated on to or incorporated within NPs (in an analogous way 
to the gadolinium ions used for MRI) include 18F, 11C, 15O, 13N, 64Cu, 124I, 68Ga, 82Rb, and 
86Y. PET imaging using 18F, which is the most widespread radionuclide probe used in this 
field, has become an established clinical tool for whole-body imaging. In light its short half-
life, its quick conjugation into the probe with a high reaction yield is necessary to improve its 
efficiency and to reduce cost. A general synthesis strategy for such 18F-labeled rare-earth 
nanoparticles was developed through a facile inorganic reaction between rare-earth cations 
(Y3+ and Gd3+) and fluoride ions [165]. The 18F-labeled rare-earth NPs were further evaluated 
by PET imaging, for their in vivo distribution and their application in lymph monitoring. 
There are, however, other types of probes and the main nanoparticle-based PET ones and their 
labeling radionuclide are reported in Table 2. 
 
Table 2. Labeling Strategies and Specific Activities of PET Radionuclides Labeled Nanoparticles and the Nuclear Characteristics of the corresponding PET Radionuclides. Adapted from Ref. [164] and up-dated.  
NPs labeling strategy radionuclide T1/2 β energy (KeV) main photon 
KeV (%) 
Ref. 
decay (%) max. Mean. 
QDs nucleophilic 
substitution 
18F 109.7 
min 
β+ (96.7) 
EC (0.1) 
634 245 511 (193.5) [166] 
  DOTA 64Cu 12.7 h β+ (17) 
EC (44) 
653 278 511 (34.8) [167] 
  DO3A 64Cu      [168] 
Iron oxide Click chemistry 18F      [34, 
169] 
  DOTA 64Cu      [170] 
[171] 
[172] 
 dithiocarbamatebis
phosphonate 
64Cu      [173] 
  Direct labeling 68Ga 67.7 m
in 
β+ (89) 
EC (11) 
1899 829 511 (178.3) [174] 
 Chelation 64Cu      [175] 
  NOTA 68Ga      [176] 
  Tyrosine 124I 4.18 d β+ (23) 
EC (77) 
2138 820 511 (46); 
603 (62.9) 
723 (10.3) 
[177] 
Aluminum 
hydroxide 
Inorganic 
interaction 
18F      [178] 
Upconversion 
nanophosphors 
Inorganic 
interaction 
18F      [137] 
[165] 
[179] 
 
Gold DOTA 64Cu      [161] 
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nanoparticle 
Gold nanoshells 
(SiO2@Au) 
DOTA 64Cu      [180] 
[181] 
Latex Direct labeling 68Ga      [182] 
  DOTA 64Cu      [183] 
  TETA, CB-TE2A 64Cu      [184] 
  BAT 64Cu      [185] 
Liposome Encapsulation 18F      [186] 
 Chelation 64Cu      [185] 
 Encapsulation 64Cu      [187] 
Solid lipid 
nanoparticle 
Encapsulation 18F      [188] 
  DTPA 68Ga      [189] 
  BAT chelate 64Cu      [190] 
Polymer Tyrosine 76Br 16.2 h β+ (55) 
EC (45) 
3941 1180 511 (109); 
559 (74) 
657 (15.9); 1854 
[191] 
  DOTA 64Cu      [192] 
  [18F] FETos 18F      [193] 
  124I      [194] 
Nanotube DOTA 64Cu      [195] 
  desferrioxamine B 89Zr 3.3 d β+ (23) 
EC(77) 
901 397  [196] 
  DOTA 86Y 14.7 h β+ (33) 3141 664 511 (63.9); 
1077 (82.5) 
[197] 
Graphene oxide 1,4,7-
triazacyclononane-
1,4,7-triacetic acid, 
66Ga 9.3 h β+ (56.5) 
EC(43.5) 
4150 - - [198] 
 
The pharmacokinetic and in vivo cancer targeting issues of 64Cu2+ ions functionalized gold 
nanocages (NCs) (64Cu-DOTA-PEGAuNCs) when followed by PET imaging in normal 
rodents revealed Au NCs size dependent [161]. 30 nm Au NCs showed much-improved in 
vivo pharmacokinetics with decreased RES system uptake and enhanced blood circulation as 
compared to 55 nm ones. The PET/CT imaging demonstrated rapid accumulation and 
centralized distribution of the 30 nm Au NCs in tumors and, more importantly, high tumor-to-
muscle ratios. PET/CT images (Figure 4) clearly showed this rapid localization of the 30 nm 
64Cu-DOTAPEG-Au NCs in tumors at 1 h post-injection even only with the administration of 
a trace amount (23.8 fmol). 
 
Figure 4 here 
 
Most of the time PET tracers are incorporated with another modality in NPs, most notably CT 
[199-202]. Figure 5 illustrates the use 18F-doped cross-linked iron oxide modified tri-modal 
NPs (18F-CLIO) to image the liver and blood pool of a mouse. The in vivo dynamic PET 
imaging showed very high signal-to-noise ratios for injected 18F-CLIO. The nanoparticle had 
a vascular half-life of 5.8 h in mice and was internalized into macrophages of liver, spleen, 
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and phagocytic cells of other lymphatic organs. The NP is additionally biodegradable and 
breaks down into elemental components within months. PET/CT allows concentrations at 2-4 
orders of magnitude lower than those required for MR imaging which likely makes PET 
imaging an important platform for clinical molecular. 
 
Figure 5 here 
 
Biocompatible inorganic NPs such as hydroxyapatite NPs also revealed as useful PET/CT 
probes [178]. They showed particularly avid and stable binding of 18F-fluoride in various 
biological media. The in vivo behaviour of the 18F-labelled hydroxyapatite particles 
determined by PET-CT imaging in mice showed that hydroxyapatite was stable in circulation 
but its accumulation in liver via reticuloendothelial clearance was followed by gradual 
degradation and release of 18F-fluoride (over a period of 4 h) which then accumulated in bone.  
 
3.2 Coupling with other contrast agents 
Among the other modalities that have been combined with PET, should be mentioned ultra-
small cancer-selective silica particles grafted with iodine and dye-doped polymers which were 
recently approved by FDA for in-human clinical trials [203], NIRF agents within the silica 
NPs [204] or QDs [168, 205, 206] and MRI [199] agents in conjunction with iron oxide 
nanomaterials [35, 171]. A bifunctional chelator (dithiocarbamate bisphosphonate, (dtcbp)) 
containing a dithiocarbamate group for binding the PET isotope 64Cu, and a bisphosphonate 
group for strong binding to Fe3O4 was elaborated. Dtcbp efficiently binds 64Cu to form the 
[64Cu(dtcbp)2] complex which is then grafted on the iron oxide NPs leading to a PET-MR 
dual modality imaging capabilities of which in vivo  accumulates in draining lymph nodes 
(Figure 6) [173].  
Figure 6 here  
However, the ratio between PET tracer and MRI contrast agent must be carefully controlled, 
because PET is extremely sensitive whereas MRI is not.  
Single-photon emission computed tomography (SPECT), a similar technique which can also 
detect nanomoles of tracer. SPECT is based on the detection of lower energy γ-emitting 
radioisotopes such as 99mTc, 111In, 123I, and 131I [14, 207-209]. As compared to PET, SPECT 
has the advantage to be more sensitive and versatile, it is cheaper and more widely available 
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as it does not rely on a local cyclotron for production of isotopes even if it is an order of 
magnitude less sensitive than PET.  
Covalent functionalization of radionuclide-filled single-walled carbon nanotubes were used as 
radio-probes [210]. The intravenous administration of these 125I loaded SWNTs was tracked 
in vivo using SPECT. Specific tissue accumulation (here lung) coupled with high in vivo 
stability prevented leakage of radionuclide to high-affinity organs (thyroid/stomach) or 
excretion, and resulted in ultrasensitive imaging and delivery of unprecedented radio-dose 
density. The nano-encapsulation of iodide within SWNTs enabled its biodistribution to be 
completely redirected from tissue with innate affinity (thyroid) to lung (Figure 7). 
Figure 7 here 
4 X-ray imaging and computed tomography (CT) 
X-ray computed tomography (CT) is one of the most powerful noninvasive diagnostic 
imaging techniques in modern medicine. It has been a clinical tool for more than half a 
century and the first widespread clinical use of NPs as X-ray contrast agents in humans were 
3 to 10-nm thorium dioxide nanoparticles [12, 211]. However due to the long-term radiation 
effects and significant carcinogenicity of the 232Th, its clinical application was rapidly given 
up. 
Iodinated molecules were then used as CT contrast agents in the clinics. They however have 
relatively short in vivo circulation times, which significantly restrict the applications of this 
technique in target-specific imaging and angiography. The use of large dose of these agents, 
which may induce serious adverse effects as well as a hypersensitivity to iodine of some 
patients, led researchers to address these issues. Over the past decade, advances in 
nanoscience brought some solutions thanks to the unique properties of nanomaterials, such as 
their prolonged circulating half-life, passive accumulation at the tumor sites, facile surface 
modification, and integration of multiple functions into a single particle, make them 
advantageous for in vivo applications [212]. 
4.1 Iodinated nanoparticles 
The widespread clinical use of iodinated compounds has encouraged the development of 
iodinated nanomaterials. Research essentially focuses [213, 214] on the incorporation of 
iodinated organic compounds into NPs, with designs ranging from emulsions, [215-218] 
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liposomes, [214, 219-223] and lipoproteins, [224, 225] to  insoluble nano objects, [214, 226-
228] and polymeric NPs, [215, 229-233]; many of them have been successfully applied in 
vivo [28, 56]. The purpose of these nanomaterials is to locally increase iodine concentrations, 
resulting in higher local contrast compared with conventional water-soluble CT contrast 
agents. A key feature of many of these NPs is their pharmacokinetics, which are often 
markedly different from those of small iodinated molecules in clinical use. They have 
increased circulation time with the subsequent implications for targeting because longer 
circulation times increase the chance of interaction and binding of the contrast agent to a 
target. 
Some multimodal nanoparticles were doped with an iodinated compound and used to enhance 
X-ray contrast [216, 224, 234, 235] as discussed in later on in the review. Iodine has a lower 
atomic number than gold and bismuth, it however exhibits higher elemental mass attenuation 
coefficient and incident X-ray energies so that when compared to gold NPs under conditions 
used for coronary angiography, iodinated contrast agents had equivalent performance [236]. 
When a contrast agent was developed by combining the two radio-dense elements iodine and 
gold within a single PAMAM dendrimer, it was demonstrated that the incorporation of both 
Au NPs and iodine-containing small molecules resulted in a significant cooperative enhancing 
effect in X-ray attenuation [237]. 
4.2 Gold nanoparticles 
In addition to the clinically used iodine, the element gold has received much attention due to 
its higher atomic number than iodine, and thus, a larger contribution of photoelectron effect to 
X-ray attenuation generating a substantial interest in gold NP-based contrast agents for in vivo 
X-ray CT. Gold nano-objects contain a large number of the contrast element (Au) as opposed 
to iodine-based nanoparticles in which iodinated molecules are often only covalently grafted 
onto the NP surface thereby lowering the concentration of the agent. Various gold, [10, 61, 
238-240] gold@dielectric hybrids, [10, 241-246] and multimodal materials, [96, 246-248] 
have been fabricated and their in vivo functionality as X-ray CT contrast agents for cancer, 
tissue-specific, and blood-pool imaging. Gold nanomaterials are currently being explored in 
multiple clinical trials and they constitute a promising next generation candidate for X-ray 
contrast materials, radiotherapy [249-251] and cancer therapy [252].  
4.3 Other contrast materials 
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Other CT molecular imaging agents have also been studied besides iodinated and gold-based 
ones. These NPs consist of bismuth sulfide and composite ceramics containing iron oxide and 
lanthanide materials. Bismuth sulfide NPs have recently been shown to have superior 
performance to iodine on a molar basis [253-255]. Even if bismuth displays similar mass 
attenuation coefficients to that of gold and a higher k-edge transition, its toxicity may prevent 
bismuth-based nanomaterials clinical use as CT agents. Other types of CT contrast agents, are 
those based on iron oxide [256] and have recently been reviewed [94, 257, 258]. A facile 
approach for fabrication of Fe3O4@Au NPs as a dual mode contrast agent for both magnetic 
resonance (MR) and computed tomography (CT) imaging applications has been performed 
via the combination of a LbL (layer by layer) self-assembly process and dendrimer chemistry 
[259]. The use of Fe3O4@Au NPs as a contrast agent for dual mode MR/CT imaging has been 
demonstrated not only for in vitro imaging of cancer cells, but also for in vivo liver imaging 
via MR and subcutaneous tissue imaging via CT.  
The high atomic weight and large number of unpaired electron makes Gadolinium an 
excellent contrasting agent both for MRI and CT imaging [12, 260-262]. Therefore, most of 
the time, NPs are at least dual probe: CT/MRI or CT/NIRF [261, 263, 264]. As an example 
Gd3+ complex-modified NaLuF4-based upconversion nanophosphors were success fully 
applied for UCL, MR and CT multi-modal imaging, by integrating NIR-to-NIR UCL, X-ray 
attenuation and paramagnetic function in one single nanoparticle. The property of NIR-to-
NIR UCL enhances the high signal-to-noise ratio of in vivo imaging of small animal. 
Moreover, Gd3+ grafting on the surface of NPs generates high r1 relaxivity for the core–shell 
nanoparticles which become suitable for T1 MR imaging. In addition, this nanoparticle with 
the core of Yb3+ and Tm3+-doped NaLuF4 shows a high X-ray attenuation and are good for CT 
imaging. The SiO2 shell reduces the toxicity of these lanthanide-based nanoparticles for small 
animals, which was confirmed by MTT assays and histological analyses. The incorporation of 
different lanthanide ions of Lu3+, Yb3+, Tm3+ and Gd3+ into one particle, 
NaLuF4:Yb3+,Tm3+@SiO2-GdDTPA, provides a facile design strategy to fabricate 
multimodality imaging agents [261].   
Yb-based NPs (NaYbF4:Er) which already revealed to be efficient upconversion 
nanophosphors (UCNPs) have also recently been identified as CT contrasts agents [265]. 
When encapsulated in a polymer (PEG) shell they showed low cytotoxicity and long 
circulation time in vivo. And a much higher efficacy as compared to the clinical iodinate 
agents commonly used. This improvement was attributed to the K-edge energy of Yb that 
locates within the higher energy region of the X-ray spectrum. Furthermore, a gadolinium 
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doping in these nanoparticles endowed them with enhanced fluorescence as well as NMR 
imaging capabilities providing clearance issues are solved.  
By virtue of its high atomic number and this well-positioned K-edge, Yb provides excellent 
spectral CT contrast both in vitro and in vivo.[266] To partly solve bioelimination and 
preliminary biodistribution issues Yb nanocolloids were used as spectral CT contrast agents. 
The synthetic approach involved an organically soluble organometallic Yb(III)-2,4-
pentadionate complex to produce polysorbate encapsulated nanocolloids of Yb incorporating 
a high density of Yb (>500K/nanoparticle) into a stable metal particle. Such high payloads of 
the Yb in the form of hydrophobic small molecule metal complexes could be obtained and 
stably concentrated into lipid-encapsulated nanocolloids and provide novel molecular imaging 
for use for spectral“multicolor” computed tomography (CT). 
5 Ultrasound (US) 
US is also a well-established clinical imaging modality. In particular, it is routinely used to 
characterize lesions in liver, urogenital tract, head and neck and soft tissues. Its main 
advantages are (i) the ability to extract molecular information (ii) portability, (iii) cost-
effectiveness, (iv) absence of ionizing irradiation, (v) high spatial and temporal resolution 
(real-time examination) and (vi) global availability. It is based on the pulse–echo principle, 
with emitted and received wave’s frequencies higher than 20 kHz. US clinical application 
involves sound waves in the range of 2–3 MHz for pediatric imaging and 5–12 MHz for adult 
imaging, providing spatial resolution in the range 0.2 to 1 mm [28].  
Contrast in US is provided by the variable ability of sound to propagate through media, 
resulting in reflection and refraction of the sound waves. Reflection and refraction depend on 
the sound itself but also on the nature of the medium and of its density. Therefore several 
microbubble-based contrast agents have been developed and are applied clinically to enhance 
the echogenicity of vasculature and organ-specific regions [267-272]. These microbubbles 
composed of surfactant, protein, and/or polymer shells containing gas cores, for example air, 
perfluorocarbons, or nitrogen should have an optimum size of 2-3 μm for common imaging 
practice [273]. Contrast agents for ultrasound imaging echogenic liposomes, [274-276] 
perfluorocarbon droplets, [277] and other materials such as gold particles, which have a 
density and compressibility substantially different from that of blood and tissue.  
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The use of nanobubbles [29, 278-286] as US contrast agents is in constant progress. Even if 
named nanobubbles they are typically in the range 150 to 1000-nm in diameter. They are 
generally composed of a perfluorocarbon gas encapsulated by a surfactant, protein, and/or 
polymer shell. The clinical significance of ultrasound as well as the labeling advantages of 
nanomaterials prompted a continued interest in developing smaller ultrasound contrast agents. 
[287-289] Despite this increasing interest, one should mention that due to lower scattering 
cross sections and often low mechanical properties of the shell, the performance of these 
nanomaterials is often inferior to that of microbubbles.  
As for other imaging techniques, there is a general trend to combine both imaging and 
therapy. A solution was proposed which consisted in a medical imaging contrast agent 
combining both NPs and microbubbles for imaging and therapy applications in a single agent 
resulting in more accurate diagnosis and local treatment of diseased tissue. Various silica-
coated NPs (e.g., CdSe/ZnS QDs, Au NRs, Fe3O4, and Gd-loaded silica NPs) were 
incorporated into highly monodisperse, microfluidic-generated compressible protein-lipid-
coated, perfluorobutane microbubbles (with size control down to 3 μm) [290]. When diluted 
in saline the NP-incorporated microbubbles are detectable using low-pressure ultrasound. 
They can be produced at high-throughput, sufficient for in vivo usage (106 MB/s).  
 
Polymeric micelles and perfluorocarbon nano/microbubble systems that encapsulated a drug, 
which can be released locally within tumor cells were also obtained; US was then used to 
determine the efficacy of this drug therapy [278, 279]. Designed redox polymer NPs were 
shown to reduce intra-cerebral hemorrhage induced by 1-MHz focused ultrasound sonication 
coupled with microbubble treatment. Sonication coupled with redox polymer NPs loaded 
microbubbles produced intra-cerebral hemorrhage but the incorporated redox polymer 
nanoparticles had a significant neuro-protective on the intra-cerebral hemorrhage-induced 
brain [291]. 
Microbubbles can potentially be used as carriers for nanoscale US contrast agents and the 
incorporation of multimodal probes with potential therapeutic applications: sonodynamic 
therapy, ultrasound-induced apoptosis, sonoporation/sonotransfection, ultrasound-induced 
drug/gas delivery, and focused ultrasound-induced thermal ablation [32, 33, 280, 292-299]. 
Very recently mesoporous silica nanocapsules were also used as ultrasound contrast agents  
and can be can be potentially used as the inorganic theranostic platform for contrast-
intensified ultrasound imaging, ultrasound-induced cytoclasis and drug release, and 
ultrasound-guided efficient HIFU tumor ablation therapy [300]. 
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6 Photoacoustic imaging (PAI) 
Photoacoustic imaging, PAI, [301] also known as laser optoacoustic imaging, is an emerging 
noninvasive, nonionizing, imaging modality that combines the high sensitivity of optical 
methods with the excellent resolution of acoustic methods [302, 303]. When illuminated by a 
short-pulsed laser, the biological sample absorbs the given light and this excitation is followed 
by a transient increase in temperature (~10 mK) and subsequent thermo-elastic expansion of 
the absorbent. This generates an ultrasonic acoustic signal, which is detected by wideband 
transducers surrounding the object and used to determine its geometry. Electromagnetic 
energy in the optical from visible to near-IR and radio-frequency regions is often utilized for 
PA excitation in soft tissues. This is not only because electromagnetic waves in these regions 
are nonionizing and safe for human use but also because they provide both high contrast and 
adequate penetration depths in biological tissues. PAI is generally performed using two main 
techniques, photoacoustic microscopy (PAM) and photoacoustic computed tomography 
(PAT). [301, 303, 304] PAM uses a coupled, focused ultrasonic detector–confocal optical 
illumination system [302] to generate multidimensional tomographic images without any 
reconstruction algorithms, whereas the detectors in PAT scan the laser-illuminated object in a 
circular path and use inverse algorithms to construct three-dimensional images [301, 305-
307]. 
While in vivo imaging with optical techniques, suffers from hemoglobin absorption and tissue 
scatter, which limit overall light penetration depth, PAI can overcome this primary drawback 
thanks to the lower ultrasonic scattering coefficients (by 2-3 orders of magnitude) of 
absorbents compared with their optical equivalents leading to ~ 5 cm depth analysis with a 
resolution of < 1 mm [308, 309]. The depth issue can even be completely eliminated when 
microwaves or radio waves (referred to as thermo-acoustic tomography (TAT)) are used as 
illumination sources [310-313].  
 
6.1 Gold-based nanomaterials 
Gold-based nanomaterials are the most significant class of materials explored for PAT 
applications. Some of those commonly used for PAT include spherical gold NPs, [304, 314-
320] nanorods, [321-327] nanostars, [328] nanocages, [305, 329-334] hollow nanoshells, 
[335] and composite materials with gold nanoshells: SiO2@Au, [306, 336, 337] Fe3O4@Au, 
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[314] cobalt@gold NPs, [110] gold-speckled silica, [316, 320] and gold nanobeacons.[338, 
339] The reasons for such an attention to gold nanosystems are many fold: they have tunable 
size- and shape-dependent plasmonic properties [340, 341] which allow them to absorb and 
scatter light from the visible to NIR region, and make them suitable for image-guided therapy 
[325, 342-344] and photothermal ablation of tumors.[345-347] A comparison of gold 
plasmonic nanostructures (surface plasmon resonance (SPR) tuned to 800 nm), revealed that 
gold nanorods and nanocages have much larger absorption and scattering cross sections than 
gold nanoshells [348].  
Gold nanorods have similarly been used as NIR photoacoustic contrast agents with high 
sensitivity [349]. Manipulation of the aspect ratio enables tuning of the SPR of the resulting 
nanorods, which has led to multiplexing applications [321, 324, 326, 327, 344]. Gold 
nanorods are also effective as tracers for noninvasive in vivo spectroscopic photoacoustic 
SLN mapping in a rat model [350].  
When they are silica-coated, gold nanorods show increased photoacoustic [344] and 
photothermal stability and retain their superior optical properties under much higher fluences 
[323, 325] when compared to PEG-coated gold nanorods which implies better imaging 
capabilities and make silica-coated gold nanorods a promising imaging and therapeutic nano-
agent for photoacoustic imaging and image-guided photothermal therapy. A recent paper 
reported the use of silica-coated gold nanorods in photoacoustic imaging for quantitation of 
mesenchymal stem cells MSCs in rodent muscle tissue. The silica coating increased the 
uptake of gold into the cell more than 5-fold, without any sign of proliferation changes in cells 
suggesting that the therapeutic benefit of the MSCs will be retained despite the presence of 
contrast agent [351]. 
Gold-based compounds have a low toxicity [13, 345, 352-355] t which makes them good 
candidates for clinical and medicinal applications [252, 354, 356]. Gold nano-objects are also 
used as multimodal systems which will be addressed later on.  
 
6.2 Carbon nanomaterials 
Carbon nanomaterials have been considered as potential biomedical materialsfor 
pharmaceutical, biomedical, [357, 358] and bio-imaging  applications, [359-362] including 
PAI [363-372] and thermo-acoustic imaging [373]. The characteristic optical properties of 
SWNTs, particularly those with optical properties in the NIR region, [374] play an important 
role in photoacoustic imaging [375].  
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As an example, single-walled carbon nanotubes conjugated with cyclic Arg-Gly-Asp (RGD) 
peptides can be used as a contrast agent for photoacoustic imaging of tumours. Intravenous 
administration of these targeted SWNTs (~ 2 nm in diameter and 50–300 nm in length) 
nanotubes to mice bearing tumors showed eight times greater photoacoustic signal in the 
tumor than mice injected with non-targeted nanotubes [376]]. Antibody-conjugated SWNTs 
targeted to integrins αvβ3-positive U87 human glioblastoma tumors in mice generated a high 
photoacoustic contrast in vivo [377] As an alternative and noninvasive approach to detection 
of the SLN, SWNTs have been shown to result in significant signal enhancement for detection 
by PAI [378]. To overcome the limitation of their relatively low absorption coefficients, the 
nanotubes are modified enhancing their NIR absorption and, thus, photoacoustic contrast. In 
one report, nanotubes were plated with a thin layer (4-8 nm) of gold; use of these golden 
carbon nanotubes (GNTs) resulted in a 100-fold increase in photoacoustic signal enhancement 
[379, 380]. The photoacoustic signals of GNTs as compared to other NIR contrast agents 
exhibited higher PA signals and correspondingly lower bubble-formation thresholds than 
those of pristine carbon nanotubes and gold nanoparticles, and comparable properties to those 
of gold nanorods and nanoshells [380-382]. The antibody-conjugated GNTs were used to 
target lymphatic vessels in vivo by PAI. In another modification of SWNTs, ICG dye 
molecules were attached to the surface of the nanotubes by π–π stacking interactions and 
showed 20-fold higher absorbance than bare SWNTs as illustrated in Figure 8 [371]. The 
synergy between the NIR absorption property of the dye and SWNT led to SWNT-ICG 
nanomaterials which provide an ~300× improvement in photoacoustic sensitivity compared 
with unmodified SWNTs in vivo.  
Figure 8 here 
In a recent work, [383] novel probe based on reduced graphene oxide (RGO)-iron oxide 
NPs(IONP) nanocomposite, was non-covalently functionalized with a biocompatible polymer, 
polyethylene glycol (PEG), for applications in multimodal imaging guided photothermal 
therapy of cancer base on PAT. Using this theranostic nanoprobe, in vivo triple modal 
fluorescence, photoacoustic, and magnetic resonance imaging are carried out, uncovering high 
passive tumor targeting, which is further used for effective photothermal ablation of tumors in 
mice. 
6.3 Other types of nanoparticles 
The encapsulation of dyes within protective NPs would certainly provide additional 
advantages in improving image contrast [384] due to signal amplification, reduced chemical 
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as well as photo-degradation, and additional ability to target specific biologically relevant 
sites [385-387]. In the selection of a dye, the relevant absorption profile is a key point but 
others can also be crucial, such as fluorescence imaging or therapeutic function such as 
photodynamic therapy (PDT) [126, 388-391]. ICG is the most commonly used for 
photoacoustic imaging in molecular and nanoparticulate formulations because it is the only 
FDA-approved dye for human applications. Its absorption peak at ~780 nm lies within the 
biological NIR window and enables deep tissue imaging only if encapsulated in NP matrices: 
organically modified silica (ORMOSIL), poly(lactic-co-glycolic acid) (PLGA), and calcium 
phosphate) due to its short plasma half-life (4 min). As such it has shown an improved 
stability and longer blood circulation time [392].  
Superparamagnetic iron oxide nanoparticles (SPION) which have been widely used as FDA 
approved contrast agents for magnetic resonance imaging (MRI) and are known to have an 
excellent safety profile [80, 81] were also analyzed for photoacoustic applications. With such 
NPs photoacoustic imaging which enhances imaging contrast by visualizing the optical 
absorption of either tissue or injected contrast agents could be coupled with magneto-motive 
ultrasound (MMUS) imaging which enhances the sensitivity and specificity of ultrasound 
based on the detection of magnetic nanoparticles perturbed by an external magnetic field. This 
integrated magneto-photo-acoustic (MPA) imaging helped identifying morphological 
properties, molecular information and complementary functional information of tissues [393]. 
The same MPA imaging used to noninvasively detect the delivery and endocytosis of NPs 
could differentiate endocytosed nanoparticles from extracellular nanoparticles in background 
tissue, and is promising for in vivo studies of cellular functionality [394]. Another study 
demonstrated the potential of core-shell iron oxide nanoparticles with silica coating as PA 
contrast agents under 1064-nm laser excitation; the increased thermo-elastic response of the 
silica-coated SPION compared to the bare ones was assumed to be due to enhanced opto-
thermal properties of the core-shell structure [395]. Besides inorganic nanoparticles there are 
also studies on the use polymeric nanoobjects for PAI.[386, 387, 396, 397]  
7 TeraHertz molecular imaging (THMI)  
Terahertz (THz, 1 THz = 1012Hz) molecular imaging (THMI) is a new analytic technique that 
detects changes in surface plasmons (SPs) emerging from nanoparticles following irradiation 
with an optical laser beam. Due to the high absorption of THz radiation in water, which is the 
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main component of biological tissues, high contrast between skin, muscle, fat, veins, nerves, 
etc can be obtained. In particular, this high sensitivity of THz to the concentration of water 
provides a high contrast between tumor (high water content) and normal tissues. Thus, 
characterizing the refractive index and absorption of various tissues is the key to the use of 
THz in the Life Sciences both for spectroscopy and imaging and in the design of biochips. 
Terahertz (THz) technology has then been advancing rapidly because of these tremendous 
potential applications. Among them, THz cancer diagnosis is drawing much attention as THz 
waves can detect the variation of cells caused by cancer, thereby rendering a new modality of 
medical imaging. Conventional THz imaging for cancer diagnosis assesses the difference in 
water content or structural changes between tumor and normal tissues. However, use of THMI 
nanoprobes improved the sensitivity of conventional THz imaging by providing a target-
specific THz image and by enabling assessment of molecular and cellular activities via 
analysis of THz waveforms [398, 399]. The sensitivity of THz electromagnetic (EM) waves to 
water molecules allows the utilization of the THz technique in diagnosing cancers because in 
cancerous tumors, diseased tissues contain more interstitial water than healthy tissues. This 
higher water content, combined with structural changes such as increased cell and protein 
density, leads to a larger THz absorption and refractive index for tissues with tumors.  
7.1 Gold nanoobjects  
THz spectroscopy is advantageous in analytical chemistry because it can detect and identify 
intermolecular interactions in chemical compounds, such as hydrogen bonds and hydrations, 
and molecular networks. Recent advances in THz components, such as ultrashort pulsed 
lasers and photoconductive antennas, have improved the sensitivity of THz time-domain 
(TDS) spectroscopy and have made the THz chemical imaging much efficient. THz chemical 
imaging can reveal hydrogen bond distributions and will be a very powerful tool in biology, 
pharmacology, and life sciences. The problem with THz cancer diagnosis is the difficulty in 
identifying the tumor in tissues at an early stage. Antibody-conjugated contrast agents for 
THz EM waves, similar to the technique adopted in MRI, may solve the problem. This was 
first performed using the so called nanoparticle-contrast agent-enabled terahertz imaging 
(CATHI) technique by targeting metal NPs such as gold nano-rods (GNRs) to cancer cells in 
tumors The THz reflection amplitude from the cancer cells with gold nano-rods (GNRs) 
increased by 20% upon infrared (IR) laser irradiation compared to cancer cells without GNRs. 
In a differential mode, the difference between the two cases was more evident because the 
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THz signal from the cancer cells with GNRs was 30 times higher than that from cancer cells 
without GNRs [398]. 
Cancer diagnosis by the terahertz molecular imaging (THMI) technique was also 
demonstrated by in vivo imaging A431 cancerous tumors in mice. The change in the THz 
response is due to the activation of the surface plasmon resonance on the surface of 
nanoparticle probes when illuminated with NIR beams. The development of a differential 
measurement technique in which the NIR beam is directly modulated instead of numerical 
subtraction of two images led to high signal-to-noise ratio (SNR) eliminating the background 
noise and generating a high sensitivity capable of identifying the miniscule differences at a 
cellular level [399]. 
7.2 Metal oxide based Nanoparticles  
Very recently, the commercially available suspension of SPIO–dextran composites (Feridex) 
was also used as not only a MRI probe but also as a THMI one. They were transfected into 
SKOV3 cancer cells, at various concentrations, and both the magnetic and optical properties 
of the particles were examined by MR and THz reflection imaging. Mice were inoculated 
with Feridex-labeled SKOV3 cells, and in vivo MR and THz images were taken 1, 3, 7, and 
14 days after inoculation. The THz images and T2* -weighted MR images showed similar 
patterns; the signal intensities of both image sets increased with Feridex concentration and 
decreased over time [93]. 
Another MRI contrast agent based on gadolinium oxide (Gd2O3) nanoparticles (GONPs) is 
receiving attention as potential multi-functional contrast agents also active in THMI [400]. 
The optical constants of GONPs were found concentration-dependent by terahertz time 
domain spectroscopy THz-TDS. Even a few μM of GONPs could be detected due to their 
power absorption capacity, which is almost three orders of magnitude larger than that of 
water. Therefore, GONPs can significantly improve the contrast in THz images. Their 
encapsulation with biocompatible materials would probably prevent aggregation problem of 
GONPs.  
As opposed to MRI technology, which has difficulty to acquire images from a surface that is 
not surrounded by water such as human skin or digestive organs, THz medical imaging 
technology, however, has uniqueness on the surface measurement of biological samples such 
as epithelial cancers. Therefore, THz imaging along with nanoparticle contrast agents will 
probably be one of the strongest imaging technique for certain diagnosis. 
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8 Ion Beam Analysis Techniques 
Besides quantum dots and gold NPs, many other inorganic nanoparticles suffer from a lack of 
fluorescence in the optical regime, and cannot be followed by light microscopy; therefore, 
there was a need for the development of X-ray fluorescence mapping which is the main way 
to detect, track and quantify nanoparticles in vitro in biological specimens. 
Ion beam analysis techniques have been widely used for the determination of chemical 
element composition of diverse types of specimens. Particle induced x-ray emission (PIXE) 
has proven to be a reliable and a highly sensitive technique for the detection and 
quantification of chemical elements in living organism. The direct analysis of biological 
samples is particularly convenient when ion beam analysis is performed with high-resolution 
microbeam, also called nuclear microprobe. The use of high-resolution microbeam offers the 
opportunity to reveal the in vitro chemical imaging of the whole cell compartments (nucleus, 
cytoplasm) and to perform trace elements quantification at the single cell level. PIXE could 
also be performed on multicellular organisms deciphering the whole elemental composition of 
defined anatomic structures of interest to address the particular questions of bioaccumulation 
and biopersistence of endogenous/exogenous chemical elements, such as metal oxide 
nanoparticles. In addition, because in vitro cell culture or microorganisms prepared for PIXE 
do not require sectioning, they can be investigated close to their natural state using cryogenic 
preparation methods.  
PIXE provides multi-elemental capability, which allows the simultaneous comparison of 
distribution of several elements inside the same specimen [401-410]. 
TiO2 is one of these nanomaterials which were largely examined by PIXE, the main reason 
being due to its extensive use in cosmetics and sunscreens. Analyses performed on the 
penetration depth and on pathways of the TiO2 particles into the skin showed a penetration of 
TiO2 particles through the stratum corneum into the underlying stratum granulosum via 
intercellular space. The TiO2 particle concentration in the stratum spinosum was below the 
minimum detection limit of about 1 particle/μm2 [411]. The state of aggregation of TiO2 NPs 
revealed to be crucial with regard to lungs toxicity [412]. The biodistributions of Pt and TiO2 
micro- and nano-sized particles in mice were estimated and visualized by X-ray scanning 
analytical microscopy. The study indicated that the difference in chemical character had a 
greater effect than did particle size. We predict that X-ray scanning analytical microscopy will 
be a useful method for studying biodistribution of micro- and nano-sized particles, because 
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this method requires no labeling or treatment of the target particles [413]. 
PIXE can even been used as a therapeutic tool because metallic nanoparticles (MNPs) are 
able to release localized x-rays when activated with a high-energy proton beam. The 
exploitation of this phenomenon in the therapeutic irradiation of tumors was then investigated. 
PIXE-based x-ray emission was directed at CT26 tumor cells in vitro, which were 
administered with either gold (average diameter 2 and 13 nm) or iron (average diameter 14 
nm) nanoparticles (GNPs or SNPs). It increased with MNPs solution concentration over the 
range of 0.1-2 mg ml-1. An in vivo study in CT26 mouse tumor models with tumor regression 
assay demonstrated significant tumor dose enhancement, thought to be a result of the PIXE 
effect when compared to conventional proton therapy (PT) without MNP (radiation-only 
group). Mice which received GNPs or SNPs injection doses of 300 mg kg-1 body weight 
before proton beam therapy exhibited from 75% to 90% tumor volume reduction (TVR) in 20 
days post-PT while the radiation-only group showed only 18% TVR and re-growth of tumor 
volume after the same timing. This approach may result in new treatment options for 
infiltrative metastatic tumors and other diffuse inflammatory diseases (Figure 9) [414]. 
Figure 9 here  
In some situations under investigation, the use of complementary PIXE and RBS facilities 
allows information to be obtained at high level of detail, yielding new understanding of the 
affected tissues and the progression of disease [406, 415]. 
The methods can produce quantitative distributions of the chemical elements obtained by 
combining PIXE with other ion beam techniques, RBS (Rutherford Backscattering 
Spectrometry) and STIM (Scanning Transmission Ion Microscopy) even if STIM is also used 
by itself [416, 417]. 
RBS is then used for sample mass normalization of PIXE signal as it provides the quantitative 
determination of the different elements in biological samples. The accurate concentration of 
the chemical elements requires the determination of the initial mass of the sample done by 
STIM analysis [411, 418-420]. As an example, visualization of the penetration of sunscreen 
formulations containing TiO2 NPs (about 20 nm primary particle size) into hair follicles of 
both human and porcine skin using these complementary methods of ion microscopy (PIXE, 
RBS, STIM) showed that the NPs were found as deep as approx. 400 µm in the follicle, 
obviously introduced mechanically rather than by a diffusive process (Figure 10) [418]. 
Figure 10 here  
 
Figure 10 shows a sagittal cut through a hair follicle of porcine skin which was exposed to an 
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isopropylmyristate gel containing TiO2 NPs and subsequently washed with water. The PIXE-
maps for P (red), S (green) and Ti (blue) are superimposed. The Ti is clearly observed on top 
of the stratum corneum as well as in the follicle surrounding the hair. The left and right 
images are identical with the Ti color code over-modulated to better visualize the Ti spots.  
 
More recent studies have used high-resolution nuclear microprobe to investigate the 
interaction of metal oxide nanoparticles with cells and multicellular organisms (Figure 11). 
Up to now, nuclear microprobe still lacks sufficient spatial resolution to resolve individual 
nanoparticles, but permit to determine detect, track and quantify metal oxide nanoparticle 
aggregates, and to assess the effect of nanoparticles on trace element homeostasis, such as 
calcium [421, 422].  
Figure 11 here  
 
Another promising research area is the study of intracellular localization of functionalized 
NPs by combining in vivo optical/epifluorescence imaging and high resolution 
PIXE/RBS/STIM analysis (Figure 12) [423]. 
Figure 12 here  
We can predict that X-ray scanning analytical microscopy will be a useful method for 
studying biodistribution of micro- and nano-sized particles, because this method requires no 
labeling or treatment of the target particles. 
9 Multimodal bio-imaging  
9.1 Multimodal techniques and instrumentation 
Multimodal bio-imaging became possible not only because of multimodal NPs [424] but also 
because the development of adapted techniques capable of combining two even three types of 
analysis in a single machine. MRI/PET probes [35] for example are powerful emerging tools, 
combining the sensitive, metabolically functional PET with the high-resolution, anatomical 
detail provided by MRI. They had a real expansion with the development of MR/PET scanner 
[425-427]. This is not the only example and this domain of multiple modality techniques will 
most likely go on growing in the future [90, 172].  
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The improvement in instrumentation and detection systems is also a crucial point enhancing 
the sensitivity of these emerging imaging techniques. Improved image-analysis software and 
expanded data storage can make existing technologies even more powerful. 
9.2 Multimodal nanoprobes 
Imaging modalities in the clinic generally include optical imaging, magnetic resonance 
imaging (MRI), computed tomography (CT), ultrasound (US) and positron emission 
tomography (PET) or single photon emission computed tomography (SPECT). A current 
popular approach to overcome their specific limitations results in combining two or more CAs 
into a single NP entity which can then be imaged by these multiple techniques either 
consecutively or simultaneously depending on the degree of development of the techniques 
[19, 171, 199-201, 281, 383, 428-438]. Combining the anatomical resolution of MRI with the 
sensitivity of optical imaging is common and constitutes a powerful technique for finding and 
quantifying the size of tumors, especially tumors or metastases that are too small for MRI 
detection alone. These MR/optical imaging agents can be used to monitor enzyme activity, in 
brain tumor imaging, and to detect and monitor apoptosis and atherosclerosis [439]. Other 
types of multimodal contrast agents [5, 25, 74, 200, 201, 281, 430, 432, 433, 436, 437, 440-
442] such as probes with three modes of imaging are considered, for example MRI/NIRF/PET 
[439], and even four [425, 439, 443, 444] which are gathered in Table 3. As an example, 
difficulty in delineating brain tumor margins is a major obstacle for further efficient treatment 
[445]. Current imaging methods are often limited by inadequate sensitivity, specificity and 
spatial resolution. To overcome this issue, Kircher et al. recently showed that a unique triple-
modality magnetic resonance imaging/photoacoustic imaging/Raman imaging nanoparticle 
(MPRNPs) could accurately help delineate the margins of brain tumors in living mice both 
preoperative and intraoperative ways. The probes were detected by all three modalities with a 
picomolar sensitivity both in vitro and in living mice. Intravenous injection of MPRs into 
glioblastoma-bearing mice led to MPRNP accumulation and retention only by the tumors. 
This provided non-invasive tumor delineation by the three modalities and through the intact 
skull. Raman imaging helped for guidance of intraoperative tumor resection because it could 
accurately delineate the tumor margins. 
 
Table 3. List of the different multimodal NPs and the type of techniques they are used for. 
Number of Type Nanoobjects ref 
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modality 
2 MRI/CT Gold NPs/ Gd3+  [245] 
  Fe3O4@Au nanocomposite particles [259] 
  Au–Fe3O4 Janus NPs [446] 
 MRI/Fluorescence QDs / iron oxide and Gd3+ NPs [447] 
  Silica NPs, Gd3+ Eu3+ and Tb3+complexes [64, 65] 
  Hydroxyapatite Gd3+ and Eu3+ complexes [448] 
  Iron-doped silicon nanoparticles [449] 
 MRI/NIRF Fe3O4@Au [450] 
  Iron oxide and Cy5.5 dye [451] 
 MRI/MRI (T1/ T2) SPIO and [452] 
  Carbon dots and Gd3+ [59] 
 MRI/PAT See the reviews [110, 200] 
 MRI/PET  [35, 425, 426, 453, 
454] 
 MRI/PET Gd3+ 64Cu [455] 
 MRI/SPECT/Fluores
cence 
Gd2O3@SiO2 and Cy 5 [171] 
 MRI/ THMI SPIOs [93] 
 MRI/US Perfluorocarbon NPS and Gd3+ [456] 
  Magnetite and PLA microbubbles [293] 
  iron oxide and 64Cu [36, 173, 175] 
 CT/Fluorescence TaOx NPs and rhodamine-B [457] 
 CT/PAT Gold@PEG NPs [239, 343] 
 CT/NIRF NaYbF4 and Tm3+ [263] 
 PET/NIRF QDs and 64Cu DOTA [205] 
 PAT/US Gold nanorods and microbubbles [32] 
  Gold Nnanorods [458] 
 SPECT/fluorescence See reviews [439, 459] 
 TAT/PAT SWNTs [378] 
 US/NIRF Proteins/Gold NPs, Iron oxide NPs, QD, [460] 
3 MRI/NIRF/PET SPIO and 64Cu and Cy5.5 [439] [171] 
 MRI/NIRF/PET Mesoporous SiO2 near-IR dye ZW800 and Gd3+ 
and 64Cu 
[124] 
  SPIO and 18F [34] 
  SPIO and 124I [235] 
  18F Yb,Er,Tm codoped NaYF4 [137] 
 MRI/CT/NIRF NaY/GdF4:Yb,Er,Tm@SiO2-Au@PEG [436] 
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  NaLuF4:Yb3+,Tm3+@SiO2-GdDTPA [261] 
  Fe3O4@NaLuF4:Yb,Er/Tm Core-shell NPs [461] 
 MRI/PAT/Raman SWNTs@PEG and iron metal NPs and 
Protamine 
[34] 
  Gd3+ and Gold NPs and trans-1,2-bis(4-pyridyl)-
ethylene 
[445] 
 MRI/PAT/ 
fluorescence 
Graphene oxide and iron oxide and dye [383] 
 MRI/CT/NIRF Perfluoro-NPs, 19F [462] 
≥ 4 MRI/PET/BRET/ 
fluorescence 
Cobalt–ferrite MNP@SiO2(RITC)-PEG/NH2 
and Luciferase protein and  68Ga 
[176] 
 MRI/MM-OCTa/US/ 
fluorescence 
SPION and RGD peptide and Nile red [463] 
 MRI/ Optic MNPs and QDs [464] 
 PET–CT/MRI/NIRF 64Cu and Iron oxide and NIR dye  [202] 
a MM-OCT: magnetomotive optical coherence tomograph. 
y 
All these combinations are expected to provide very precise and detailed information for clear 
diagnosis and to be more efficient than a single modality. However, it should be stated that 
the rational selection of the different imaging modalities to put on a single probe is highly 
crucial. During the design of these multimodal imaging probes, the enhancement of one 
modality must not be at the expense of another and researchers should rationally avoid 
overlapping of advantages and rather compensate for the weak points of each modality so as 
to maximize the overall synergistic effect. Generally, imaging modalities with high sensitivity 
(PET, optical, etc.) are combined with others which will exhibit high spatial resolution (MR, 
CT, etc.) (Table 1). 
Furthermore, these bio-imaging techniques require different administered doses, based on the 
technique’s sensitivity, host biology, route of delivery, and the targeting strategy used. The 
controlling the ratios of the different types of agents on a single probe, becomes compulsory 
so as to obtain the perfect SNR for each modality. Additionally, the incorporation of more 
than one modality may cause interferences between the two, iron-based MRI agents 
quenching fluorescence agents for example, and complicate the synthetic aspect. Succeeding 
in this approach would lead to the administration of a single dose of multiple agents to the 
patient, resulting in a potential reduction of side effects.  
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10 Functionalization 
Most disease processes occur at the molecular and cellular levels, therefore researchers have 
to face breakthrough in precisely viewing and understanding these processes. The ideal 
imaging resolution they want to reach is a few nanometers, the length scale of most 
biological. With this in mind the functionalization of NPs becomes crucial for their use in 
diagnostic and therapeutic applications. The research on the functionalization of NPs for bio-
imaging applications has been reviewed [25, 98, 360, 465-471]. The preparation of NPs for 
bio-imaging applications can include a variety of steps: synthesis, coating, surface 
functionalization, and bioconjugation. The most common strategies of engineering NP 
surfaces involve physical adsorption or chemisorption of the desired ligands onto the surface. 
Chemisorption or covalent linkages are preferred, and the coated NPs should possess high 
colloidal stability, biocompatibility, water solubility, as well as functional groups for further 
bioconjugation. Functionalization techniques reported in the literature suffer from limitations 
such as complex synthesis steps, poor biocompatibility, low stability, and hydrophobic 
products. Therefore, coating strategies based on chemisorption and ligand exchange often 
provide a better way to finely tune the surface properties of NPs. After conjugation with the 
appropriate targeting ligands, antibodies, or proteins, fluorescent NPs also exhibit highly 
selective binding, making them useful for targeting and imaging. 
 
Table 4. List of the different functionalization processes of NPs from [465]. 
Reaction type Functionalized NP Reactant  Final NP 
Michael addition 
 
  
Epoxide opening 
   
Addition of 
amine to 
cyanates 
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Amide bond 
formation  
 
 
Amide bond 
formation  
 
 
Amide bond 
formation  
 
 
Imine bond 
formation  
 
 
Imine bond 
formation  
 
 
Click chemistry 
 
 
 
Ring closing or 
opening 
metathesis 
   
Diels-Alder 
reaction 
  
 
 
Synthesis of NPs leads to two major categories: hydrophobic and hydrophilic NPs, 
respectively. Many NPs, mainly QDs and metal NPs are hydrophobic in nature, causing 
insolubility in water and preventing further functionalization. Thus, water solubilization and 
functionalization become key points prior to any applications of the NPs. Their coating 
chemistry is critical to provide colloidal stability and water-soluble, robust NPs with flexible 
39 
 
surface chemistry. The most common functionalization strategies are (i) direct encapsulation 
of the hydrophobic NPs by hydrophilic polymers or a silica coating and (ii) ligand exchange 
of the original surfactant with hydrophilic ligands, such as thiols.  
Regardless of composition, surface functionalization of the nanomaterial is required to enable 
targeting and stealth for long circulation times with minimal nonspecific binding [239]. There 
is a plethora of entities that can be incorporated onto a NP’s surface, with covalent bonding 
preferred over electrostatic interactions: DNA, RNA, [472] oligonucleotides (aptamers), [29, 
434, 473-476] peptides, [36, 175, 201, 477-482] proteins, [483-487] enzymes, [488-491] 
antibodies [492]. No matter what the surface moiety, its activity must not be altered once 
anchored to the NP surface (Figure 13).  
Figure 13 here 
 
Routes of delivery and bioavailability are also important concerns in which functionalization 
is crucial. The most common delivery route is intravenous injection which requires an 
optimization of NPs circulation time since they must be able to pass through the bloodstream 
and reach their desired target intact. Their surface functionalization generally results in size 
increase due to the added shell (silica, PEG, poloxamines, poloxamers, polysaccharides). This 
size increase may be detrimental for vasculature permeability and may affect bloodstream 
circulation especially through thin capillaries.  
In addition to intravenous (IV) administration, intramuscular injections, oral, transdermal, and 
inhalation routes are also possible and NPs must be able to survive their particular delivery 
route. The probe, to be effective must perform the desired function or bind properly to the 
desired target so that any loss of biological activity of the component conjugated to the NP 
surface must be determined beforehand.  
Functionalization can also help addressing NPs toxicity aspects [12, 354, 358, 465, 468, 493, 
494]. Indeed, properly protected NPs conjugated or coated with biocompatible materials can 
be used for the fabrication of various functional systems with multimodality as well as 
targeting properties, reduced toxicity and proper removal from the body. 
Furthermore, governmental institutions should require a standardization process of NPs 
characterizations (as particle size, shape, dissolution rate, agglomeration state, and surface 
area and chemistry) [495] as well as toxicity assays. It has generally been assumed that in 
vitro toxicity tests designed for soluble chemicals are appropriate for nanomaterials. However 
extrapolation of in vitro toxicology findings to humans is not so obvious when the mode of 
action and/or metabolic conditions in the cell culture model may not be relevant in humans 
40 
 
[496-498]. This is not an easy task, since the standardized established tests should work for 
multiple particle types, despite the fact that these NPs have different characteristics and 
behaviors (fluorescence, magnetism, metallic nature…) but it should definitely be undertaken. 
When such NPs are used in bio-imaging , it is also crucial to have accurate characterization to 
fully understand (i) their structure–function relationship such as particle number and dose 
administered so as to make the right balance between safety and good SNRs, (ii) their 
behavior in the biological environment (e.g., dispersibility or aggregation), and (iii) the 
interactions between the functionalized surface of the NP and the target of interest (i.e., 
binding kinetics and thermodynamics).  
 
11 Perspectives: Multimodal Theranostic NPs 
To successfully translate multimodal NPs into clinical treatment, several issues have to be 
taken into consideration such as (i) reasonable blood half-life; (ii) favorable physiological 
behavior with minimal off-target; (iii) any possible metabolism to clearable components; (iv) 
effective clearance of NPs from the human body; and (v) their potential toxicity for living 
subjects and humans. So when adequately modified multimodal nanoprobes can also become 
theranostic NPs. They are then essentially found in cancer research where they provide the 
diagnostic capability using an imaging modality to detect a tumor, while supplying the 
component for therapy against this specific tumor type, commonly utilizing photothermal 
ablation (PTA) or photodynamic therapy (PDT). PTA works by exciting a NP with a large 
absorption cross section (e.g., gold), which causes a localized heating that then kills the tumor 
cells into which the NPs have been injected [337]. Once more gold-based nanoobjects are 
numerous: gold nanoshells and nanocages surrounding a silica core have been used in photo-
ablative therapies [329, 345-347, 356, 499-503] even if PTA has also been used with SWNTs 
[504].  
PDT uses photosensitizers that, when excited by light, react with molecular oxygen in the 
biological environment to produce ROS, which are cytotoxic to cells. Multifunctional NPs 
used for multimodal imaging and theranostic applications have been reviewed [8, 126, 150, 
388-391, 416, 481, 505-508]. One material that may prove useful in combining a dual 
imaging and therapy is mesoporous silica NPs; with their large surface areas and pore 
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volumes, one or two modalities (optical imaging agent and an anticancer drug) can be 
incorporated into the silica matrix while loading the other modality into its pores. [509-511]  
Encapsulating drug payloads in NPs can prevent exposure of healthy cells to the cytotoxic 
drug and may prove more beneficial (e.g., lower toxicity and fewer side effects) at lower 
doses than the free drug. However, this can reveal much more complex than the use of simple 
small-molecule drugs that are easily characterized. In addition, the NP must remain intact 
until reaching the tumor site and then release the drug controllably through its desired 
mechanism—issues that will require further research and development.  
Due to their nanoscale dimensions and high aspect ratio, single-walled carbon nanotubes 
(SWCNTs) have been used as a high drug loading transporter for anti-cancer drugs, as they 
are capable of penetrating mammalian cell membranes. The triple functionalization of 
oxidized SWCNTs with the anti-cancer drug doxorubicin, a monoclonal antibody, and a 
fluorescent marker at non-competing binding sites allowed for targeted delivery of drug to 
cancer cells and visualization of their cellular uptake by confocal microscopy. An intracellular 
release of doxorubicin (DOX).was observed which then translocated to the nucleus while the 
nanotubes remain in the cytoplasm [512]. 
Other important areas in which multimodal NPs can be beneficial include (i) tumor imaging 
for guided surgery, [323, 513-516] imaging of gene expression in vivo to elucidate disease 
development, [287, 288, 296, 370, 517-520] drug delivery [471] and efficacy of anti-cancer 
drugs [234, 337, 429, 498, 521-525].  
 
In the next future, NPs will not only be used as contrast agents not simply to find and 
delineate tumors, but also aim at elucidating the biological processes and cellular mechanisms 
so as to understand and hopefully cure other diseases than cancer, such as Alzheimer’s, 
Parkinson’s, multiple sclerosis, rheumatoid arthritis, and diabetes.  
Major developments of the future should then concern diagnosis as well as treatment with 
therapeutic NPs. These new agents to be developed from a societal point of view will have to 
prove as highly superior to any currently existing system with the same function. Therefore, 
the development of CAs incorporating an additional functionality (i.e., therapeutic agent, 
measure of disease progression, or evaluation of treatment effectiveness) with the classical in-
vivo imaging modality will most likely be expanded, especially if based on some already-
approved material. 
Additional types of NP contrast agents may see development in the future. These smart 
responsive probes that turn “on” or “off” when exposed to the target or given conditions are 
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being developed. Two fluorochromes (Cy5.5) cleavable by proteases, and (Cy7) which serves 
as an internal standard were grafted on superparamagnetic iron oxide NPs  leading to a dual 
fluorochrome optical probe which reacted to the presence of protease enzymes in its 
environment with a change in signal (700% increase in fluorescence) [526].  
Tumor cells have a more acidic internal environment compared with normal cells (most 
cancer tissues have lower extracellular pH values (pH 6.0–7.0) than normal tissues (pH 7.4), 
and the pH drops further in tumor cells, especially inside endosomes (4.5–5.5), which 
provides a high possibility to control the drug release behaviors through the use of pH-
sensitive vehicles. Many systems exploiting this pH modification  are under scrutiny [527]. 
Well-defined core@shell (MCNC@PAA) nanospheres based on a 100 nm sized magnetic 
colloid nanocrystal cluster core and across-linked poly(acrylic acid) (PAA) shell were for 
example loaded with of doxorubicin (DOX). [528] The experimental results showed that (i) 
the MCNC@PAA NPS could achieve a high drug loading content and entrapment efficiency; 
(ii) a synergistic pH-responsive effect derived from the entrapped DOX and PAA network 
was found to effectively manipulate the drug releasing behavior at 37 °C. In fact the 
premature release was highly restricted at a pH of 7.4, while upon more acidic ones pH (from 
7.4 to 5.0 or 4.0), a large amount of the drug was rapidly released. The in vitro cellular 
cytotoxicity test proved they are highly biocompatible and suitable for use as a drug carrier in 
CDDS and that MCNC/PAA–DOX show a higher cytotoxicity compared with that of free 
DOX to HeLa cells. Other pH-sensitive based NPs have been used such as chitosan [529] 
polymers, [530] core@shell NPs [527], nanogels [531]. Among stimuli sensitive NPs are light 
sensitive one. For example, light-stimulated remote release of nucleic acid has been attempted 
by utilizing the tunable optical properties and moderating Au–S bond strength of various gold 
nanomaterials [532, 533]. For example, temporally and spatially controlled delivery of siRNA 
using (NIR)-sensitive gold nanoshell-siRNA conjugates was explored [534]. Pulsed NIR laser 
irradiation, after their easy cellular uptake by TAT-lipid attached on the gold nanoshell, 
triggered siRNA release and resulted in efficient gene silencing in vitro. A remote optical 
switch for localized and selective control of RNA interference was also achieved using gold 
nanorods conjugated with thiol-modified sense strand of double stranded oligonucleotides 
[535]. Some of these NPs are dual probes with both photo- and pH- responsive properties 
[536]. 
A recent review by Kwon et al. on stimuli-responsive polymers and nanomaterials for gene 
delivery and imaging applications came out in which they introduces the recent advances in 
tackling the key challenges in achieving efficient, targeted, and safe non-viral gene delivery 
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using various nucleic acid-containing nanomaterials that are designed to respond to various 
extra- and intracellular biological stimuli (pH, redox potential, and enzyme) as well as 
external artificial triggers (light and ultrasound). Nanomaterials platform for combined 
imaging and gene therapy, nanotheranostics, using stimuli-responsive materials was also 
highlighted in this review. It is clear that developing novel multifunctional l vectors, which 
transform their physico-chemical properties in response to various stimuli in a timely and 
spatially controlled manner, is highly desired to translate the promise of gene therapy for the 
clinical success. Temperature-sensitive NPs have been identified many of them including heat 
activable iron oxide and thermo-sensitive polymers, [537-547] silica NPs, [542, 544, 548] 
liposomes, [548-550] micelles, [551] multifunctional nanoparticles containing both CdTe 
quantum dots (QDs) and Fe3O4 magnetic particles [552]. 
These nanomaterials CAs will certainly find more than numerous applications as tunable, 
remotely controlled platforms for drug delivery, hyperthermia cancer treatment, and various 
other biomedical applications. The basis for the interest lies in their unique properties 
achieved at the nanoscale that can be accessed via remote stimuli. These properties could then 
be exploited to simultaneously activate secondary systems that are not remotely actuatable 
[440, 535, 536, 553-561]. Despite all the work already performed, Richard Feynman is still 
more than right: “There is still Plenty of Room at the Bottom”.  
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Caption to figures: 
Figure 1. In vivo testing of the (Tf)-SPION conjugate in rats bearing 9L gliosarcoma tumors. 
Two tumors expressing either a high (9L3.9) or a low (9L4.2) level of the TfR were imaged 
before injection and 72 hours after injection of Tf-SPION particles. Reprinted with permission 
from [95]. Copyright (2003) Neoplasia Press. 
Figure 2. In vivo five-color lymphatic drainage imaging pointing at five distinct lymphatic 
drainages. (a) In vivo and intra-surgical spectral fluorescence imaging of a mouse injected 
with five carboxyl QDs (565, blue; 605, green; 655, yellow; 705, magenta; 800, red) intra-
cutaneously into the middle digits of the bilateral upper extremities, the bilateral ears, and at 
the median chin, as shown in the right hand side schema. Five primary draining lymph nodes 
were simultaneously visualized with different colors through the skin in the in vivo image and 
were more clearly seen in the image taken at the surgery. Reprinted, with permission, from 
Ref. [117], Copyright (2007) American Chemical Society.  
Figure 3. a) In vivo images of LPSiNPs and Dextran-coated-LPSiNPs. The mice were imaged 
at multiple time points after intravenous injection of LPSiNPs and Dextran-coated-LPSiNPs 
(20 mg kg-1). Arrowheads and arrows with solid lines indicate liver and bladder, respectively. 
b) Lateral image of the same mice shown in a), 8 h after LPSiNP or Dextran-coated-LPSiNP 
injection. Arrows with dashed lines indicate spleen. Reprinted by permission from Macmillan 
Publishers Ltd from Ref. [160]. Copyright (2009) Nature Publishing Group.  
Figure 4: PET/CT images of the 30 nm 64Cu-DOTA-PEG-Au NCs in a mouse bearing an 
EMT-6 tumor at 1, 4, and 24 h post- injection (3.7 MBq injection/mouse). T, tumor; B, 
bladder. The increase of tumor-to-muscle ratios was consistent with the biodistribution 
measurements. Reprinted, with permission, from Ref. [161]. Copyright (2012) American 
Chemical Society.  
Figure 5. Dynamic PET/CT imaging of BALB/C mouse injected with 18F-CLIO. Merged 
PET/CT coronal images at 2 h (a), 7 h (b), and 16 h (c) post-injection of 18F-CLIO. PET only 
coronal images at 2 h (d), 7 h (e), and 16 h (f) post-injection of 18F-CLIO. CT only coronal 
image (g). Three-dimensional merged PET-CT images at 2 h (h) and 16 h (i) post-injection. 
The green arrow indicates blood pool region of interest (ROI) and the asterisk indicates liver 
ROI. Reprinted, with permission, from Ref. [34]. Copyright (2009) American Chemical 
Society.  
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Figure 6. In vivo PET–MR imaging studies with [64Cu(dtcbp)2]-Fe3O4 NPs in mouse. A,B) 
Coronal (top) and short axis (bottom) MR images of the lower abdominal area and upper hind 
legs showing the popliteal lymph nodes (solid arrows) before (A) and after (B) footpad 
injection of [64Cu(dtcbp)2]-Fe3O4. C) Coronal (top) and short-axis (bottom) Nano PET–CT 
images of the same mouse as in (B) showing the uptake of the NPs in the popliteal (solid 
arrow) and iliac lymph nodes (hollow arrow). D) Whole-body NanoPET–CT images showing 
sole uptake of [64Cu(dtcbp)2]-Fe3O4in the popliteal and iliac lymph nodes. No translocation of 
radioactivity to other tissues was detected. Reprinted, with permission, from Ref. [173]. 
Copyright (2011) John Wiley and Sons. 
Figure 7. Whole-animal SPECT/CT imaging, immediately after tail intravenous injection 
administration of filled, functionalized SWNTs (left hand side); and radionuclide alone (right 
hand side). Reprinted, with permission, from Ref. [210]. Copyright (2010) Nature Publishing 
Group. 
Figure 8. Photo-acoustic detection of SWNT-ICG in living mice. (a) Mice were injected 
subcutaneously with SWNT-ICG at various concentrations - 0.82–200 nmol L-1). The images 
represent ultrasound (gray) and photoacoustic (green) vertical slices through the subcutaneous 
injections (dotted black line). The skin is visualized in the ultrasound images, and the 
photoacoustic images show the SWNT-ICG distribution. The nanobeacons on the images 
illustrate the approximate edges of each inclusion. (b) The photoacoustic signal from each 
inclusion was calculated using 3D regions of interest and the “background” represents the 
endogenous signal measured from tissues. Linear regression (R2 = 0.97) of the photoacoustic 
signal curve indicates that 170 pmol.L−1 SWNT-ICG will give the equivalent background 
signal of tissues. Reprinted, with permission, from Ref. [371], Copyright (2010) American 
Chemical Society.  
Figure 9. Description of proton beam irradiation on tumor tissue in the presence of metallic 
NPs. Tumor-associated macrophage, distributed in tumor periphery, uptakes metallic 
nanoparticles, which produces a therapeutic effect potentially on TAM and infiltrated tumor 
cell by proton-induced X-ray emission (PIXE) effect. Reprinted, with permission, from Ref. 
[414]. Copyright (2010) IOP Publishing Ltd. 
Figure 10. Sagittal cut through a hair follicle of porcine skin exposed to a formulation 
containing nanosized TiO2. PIXE-data were taken with 2.25 MeV protons at 100 pA and a 
charge of 0.5 µC. The scan size is 400 µm×400 µm, on 256×256 pixels and a lateral 
resolution around 1 µm. The formulation with NPs (blue) is deeply pushed into the follicle. 
Reprinted, with permission, from Ref. [418]. Copyright (2007) Elsevier. 
Figure 11. a) Density map (STIM) and in situ 2D chemical imaging (PIXE) of HaCat cells 
exposed to titanium oxide NPs. Control HaCat cells (left panel) and HaCat cells exposed to 
titanium oxide NPs (right panel) have been investigated using phase contrast imaging and 
STIM/PIXE analysis. The simultaneous combination of STIM and PIXE reveals the specific 
in situ chemical distribution in the whole cellular body. A specific pattern is observed for the 
phosphorus distribution which is mainly located in the cell nucleus. Titanium is only detected 
in exposed cells with disperse but punctuated distribution in the cellular body. Scale bar, 10 
µm. b) High resolution confocal image of paraformaldehyde-fixed PHFK cells treated with 
Fluorecein-TiO2-NPs (green) at a final concentration of 2 mg/cm2 for 24 h and treated for 
immunofluorescence with propidium iodide (PI) (cytoplasm and nucleolus, red) and 
Hoechst33342 (nucleus, blue): top Fluorescence image, bottom 3D reconstruction.  
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Figure 12. Density map (STIM) and in situ chemical imaging (PIXE) of a lyophilized adult C. 
elegans exposed to titanium oxide nanoparticles. (top) STIM rendition of the whole C. 
elegans body. Regions of interest corresponding to buccal cavity, pharynx corpus 
(metacorpus), pharyngeal posterior part with terminal bulb and anterior part of the intestine 
(GUT) are shown. Intestinal cells can be also seen between gut and uterus which is full of 
fertilized eggs. (bottom) 2D maps of phosphorus (green), sulfur (red) and titanium (blue) in 
the whole C. elegans body. Co-localization map reveals a highly specific distribution of 
element in organs suggesting a link between chemical anatomical structure and their 
functions. The titanium oxide nanoparticles ingestion is demonstrated by the presence of 
titanium in the pharyngeal metacarpus and in the rectum. Phosphorus (green), sulfur (red) and 
titanium (blue). Scale bar, 20 µm. 
Figure 13. Different types of surface functionalization and morphologies of inorganic NPs. 
Reprinted with permission from [12] Copyright (2012) John Wiley and Sons. 
 
 
Figure 14. In vivo testing of the (Tf)-SPION conjugate in rats bearing 9L gliosarcoma tumors. 
Two tumors expressing either a high (9L3.9) or a low (9L4.2) level of the TfR were imaged 
before injection and 72 hours after injection of Tf-SPION particles. Reprinted with permission 
from [95]. Copyright (2003) Neoplasia Press. 
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Figure 15. In vivo five-color lymphatic drainage imaging pointing at five distinct lymphatic 
drainages. (a) In vivo and intra-surgical spectral fluorescence imaging of a mouse injected 
with five carboxyl QDs (565, blue; 605, green; 655, yellow; 705, magenta; 800, red) intra-
cutaneously into the middle digits of the bilateral upper extremities, the bilateral ears, and at 
the median chin, as shown in the right hand side schema. Five primary draining lymph nodes 
were simultaneously visualized with different colors through the skin in the in vivo image and 
were more clearly seen in the image taken at the surgery. (Reprinted, with permission, from 
Ref. [117], Copyright (2007) American Chemical Society) 
 
 
Figure 16. a) In vivo images of LPSiNPs and Dextran-coated-LPSiNPs. The mice were 
imaged at multiple time points after intravenous injection of LPSiNPs and Dextran-coated-
LPSiNPs (20 mg kg-1). Arrowheads and arrows with solid lines indicate liver and bladder, 
respectively. b) Lateral image of the same mice shown in a), 8 h after LPSiNP or Dextran-
coated-LPSiNP injection. Arrows with dashed lines indicate spleen. Reprinted by permission 
from Macmillan Publishers Ltd from Ref. [160]. Nature Materials. Copyright 2009. 
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Figure 17: PET/CT images of the 30 nm 64Cu-DOTA-PEG-Au NCs in a mouse bearing an 
EMT-6 tumor at 1, 4, and 24 h post- injection (3.7 MBq injection/mouse). T, tumor; B, 
bladder. The increase of tumor-to-muscle ratios was consistent with the biodistribution 
measurements. Reprinted, with permission, from Ref. [161], Copyright (2012) American 
Chemical Society. 
 
Figure 18. Dynamic PET/CT imaging of BALB/C mouse injected with 18F-CLIO. Merged 
PET/CT coronal images at 2 h (a), 7 h (b), and 16 h (c) post-injection of 18F-CLIO. PET only 
coronal images at 2 h (d), 7 h (e), and 16 h (f) post-injection of 18F-CLIO. CT only coronal 
image (g). Three-dimensional merged PET-CT images at 2 h (h) and 16 h (i) post-injection. 
The green arrow indicates blood pool region of interest (ROI) and the asterisk indicates liver 
ROI. Reprinted, with permission, from Ref. [34], Copyright (2009) American Chemical 
Society. 
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Figure 19. In vivo PET–MR imaging studies with [64Cu(dtcbp)2]-Fe3O4 NPs in mouse. A,B) 
Coronal (top) and short axis (bottom) MR images of the lower abdominal area and upper hind 
legs showing the popliteal lymph nodes (solid arrows) before (A) and after (B) footpad 
injection of [64Cu(dtcbp)2]-Fe3O4. C) Coronal (top) and short-axis (bottom) Nano PET–CT 
images of the same mouse as in (B) showing the uptake of the NPs in the popliteal (solid 
arrow) and iliac lymph nodes (hollow arrow). D) Whole-body NanoPET–CT images showing 
sole uptake of [64Cu(dtcbp)2]-Fe3O4in the popliteal and iliac lymph nodes. No translocation of 
radioactivity to other tissues was detected. Reprinted, with permission, from Ref. [173]. 
Copyright (2011) John Wiley and Sons. 
 
 
Figure 20. Whole-animal SPECT/CT imaging, immediately after tail intravenous injection 
administration of filled, functionalized SWNTs (left hand side); and radionuclide alone (right 
hand side). Reprinted, with permission, from Ref. [210]. Copyright (2010) Nature Publishing 
Group. 
81 
 
 
Figure 21. Photo-acoustic detection of SWNT-ICG in living mice. (a) Mice were injected 
subcutaneously with SWNT-ICG at various concentrations - 0.82–200 nmol L-1). The images 
represent ultrasound (gray) and photoacoustic (green) vertical slices through the subcutaneous 
injections (dotted black line). The skin is visualized in the ultrasound images, and the 
photoacoustic images show the SWNT-ICG distribution. The nanobeacons on the images 
illustrate the approximate edges of each inclusion. (b) The photoacoustic signal from each 
inclusion was calculated using 3D regions of interest and the “background” represents the 
endogenous signal measured from tissues. Linear regression (R2 = 0.97) of the photoacoustic 
signal curve indicates that 170 pmol.L−1 SWNT-ICG will give the equivalent background 
signal of tissues. Reprinted, with permission, from Ref. [371], Copyright (2010) American 
Chemical Society.  
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Figure 22. Description of proton beam irradiation on tumor tissue in the presence of metallic 
NPs. Tumor-associated macrophage, distributed in tumor periphery, uptakes metallic 
nanoparticles, which produces a therapeutic effect potentially on TAM and infiltrated tumor 
cell by proton-induced X-ray emission (PIXE) effect. Reprinted, with permission, from Ref. 
[414]. Copyright 2010 IOP Publishing Ltd. 
 
Figure 23. Sagittal cut through a hair follicle of porcine skin exposed to a formulation 
containing nanosized TiO2. PIXE-data were taken with 2.25 MeV protons at 100 pA and a 
charge of 0.5 µC. The scan size is 400 µm×400 µm, on 256×256 pixels and a lateral 
resolution around 1 µm. The formulation with NPs (blue) is deeply pushed into the follicle. 
Reprinted, with permission, from Ref. [418]. Copyright 2007 Elsevier. 
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Figure 24. a) Density map (STIM) and in situ 2D chemical imaging (PIXE) of HaCat cells 
exposed to titanium oxide NPs. Control HaCat cells (left panel) and HaCat cells exposed to 
titanium oxide NPs (right panel) have been investigated using phase contrast imaging and 
STIM/PIXE analysis. The simultaneous combination of STIM and PIXE reveals the specific 
in situ chemical distribution in the whole cellular body. A specific pattern is observed for the 
phosphorus distribution which is mainly located in the cell nucleus. Titanium is only detected 
in exposed cells with disperse but punctuated distribution in the cellular body. Scale bar, 10 
m. b) High resolution confocal image of paraformaldehyde-fixed PHFK cells treated with 
Fluorecein-TiO2-NPs (green) at a final concentration of 2 mg/cm2 for 24 h and treated for 
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immunofluorescence with propidium iodide (PI) (cytoplasm and nucleolus, red) and 
Hoechst33342 (nucleus, blue): top Fluorescence image, bottom 3D reconstruction.  
 
 
Figure 25. – Density map (STIM) and in situ chemical imaging (PIXE) of a lyophilized adult 
C. elegans exposed to titanium oxide nanoparticles. (top) STIM rendition of the whole C. 
elegans body. Regions of interest corresponding to buccal cavity, pharynx corpus 
(metacorpus), pharyngeal posterior part with terminal bulb and anterior part of the intestine 
(GUT) are shown. Intestinal cells can be also seen between gut and uterus which is full of 
fertilized eggs. (bottom) 2D maps of phosphorus (green), sulfur (red) and titanium (blue) in 
the whole C. elegans body. Co-localization map reveals a highly specific distribution of 
element in organs suggesting a link between chemical anatomical structure and their 
functions. The titanium oxide nanoparticles ingestion is demonstrated by the presence of 
titanium in the pharyngeal metacarpus and in the rectum. Phosphorus (green), sulfur (red) and 
titanium (blue). Scale bar, 20 µm. 
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Figure 26. Different types of surface functionalization and morphologies of inorganic NPs. 
Reprinted with permission from [12] Copyright 2012 John Wiley and Sons. 
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